

DUKE UNIVERSITY MEDICAL CENTER

CURRICULUM VITAE

Date Prepared: April 7, 2017

Name: GILLIAN DENISE SANDERS SCHMIDLER, PH.D.

Primary academic appointment: Professor of Medicine (Tenured)

Primary academic department: Department of Medicine, Division of Clinical Pharmacology

Secondary appointment: Associate Professor of Biostatistics and Bioinformatics

Present academic rank and title: Professor of Medicine (Tenured)

Date and rank of first Duke Faculty appointment: 11/1/2003, Associate Professor in Medicine

Medical Licensure: NA

Date of birth: 10/3/1971 Place: Winnipeg, Manitoba Canada

Citizen of: United States and Canada

<u>Education</u>	<u>Institution</u>	<u>Date</u>	<u>Degree</u>
High School	St. Johns Ravenscourt Winnipeg, Manitoba Canada	1989	Diploma
College	Princeton University Princeton, New Jersey	1993	A.B., Mathematics
Graduate	Stanford University Stanford, CA	1998	Ph.D., Medical Information Sciences

Scholarly societies: Sigma Xi (1993 –)

Professional training and academic career (chronologically, beginning with first postgraduate position):

1998	Engineering Research Associate in the Department of Health Research and Policy, Division of Health Services Research, Stanford University, Stanford, CA
10/1998 – 8/1999	Acting Assistant Professor (Research) in the Department of Medicine/ Center for Primary Care and Outcomes Research, Stanford University, Stanford CA
09/1999 – 10/2003	Assistant Professor (Research) in the Department of Medicine/ Center for Primary Care and Outcomes Research and in the Department of Health Research and Policy (by courtesy), Stanford University, Stanford CA
11/2003 – 03/2014	Associate Professor in Medicine, Division of Clinical Pharmacology, Duke University Medical Center, Durham NC
11/2003 – 03/2014	Assistant Professor of Biostatistics and Bioinformatics, Duke University, Durham NC
12/2003	Senior Fellow in Clinical Health Policy, Duke Center for Clinical Health Policy Research,

Duke University, Durham NC

01/2005	Health Services Research and Development Research Associate, Durham Veterans Affairs Medical Center, Durham NC
10/2005 – present	Co-Director, Duke Center for the Prevention of Sudden Cardiac Death, Duke University, Durham NC
2008 – 2009	Social Science Research Institute (SSRI), Duke University, Faculty Fellow, Program in Medical Decision Making
07/2009 – 2012	Director, Duke AHRQ Evidence-Based Practice Center (EPC III)
2012 – present	Director, Duke Evidence Synthesis Group (Duke ESG)
03/2014—06/2016	Associate Professor in Medicine (Division of Clinical Pharmacology) and in Biostatistics and Bioinformatics (Tenured), Duke University Medical Center, Durham NC
12/2014—present	Director, Duke AHRQ Evidence-Based Practice Center (EPC V)
1/2016—12/2016	Duke School of Medicine ALICE Program – Academic Leadership, Innovation, and Collaborative Engagement
07/2016—present	Professor in Medicine (Division of Clinical Pharmacology) and Associate Professor in Biostatistics and Bioinformatics (Tenured), Duke University Medical Center, Durham NC
02/2017—present	Faculty Council, Duke Clinical Research Institute

PUBLICATIONS

Refereed journals

1. **Sanders GD**, Lyons EA. The potential use of expert systems to enable physicians to order more cost-effective diagnostic imaging examinations. *Journal of Digital Imaging*, May 1991; 4(2): 112-122. PubMed PMID: 2070003.
2. Kahn CE, **Sanders GD**, Lyons EA, Kostelic JK, MacEwan DW, Gordon WL. Computed tomography for nontraumatic headache: current utilization and cost-effectiveness. *Canadian Association of Radiologists Journal*. 1993 June 44(3): 189-93. PubMed PMID: 8504331.
3. **Sanders GD**, Owens DK, Padian N, Cardinalli, AB, Sullivan AN, Nease RF. A computer-based interview to identify HIV risk behaviors and to assess patient preferences for HIV-related health states. *Journal of the American Medical Informatics Association* 1994; Annual Supplement: 20-24. PubMed PMID: 7949919; PubMed Central PMCID: PMC2247747.
4. Henrion M, Provan G, del Favero B, **Sanders GD**. An experimental comparison of numerical and qualitative probabilistic reasoning. *Proceedings of the Tenth Conference in Uncertainty in Artificial Intelligence*, Edited by Ramon Lopez de Mantaras and David Poole, Morgan Kaufmann Publishers, San Francisco, 1994: 319-326 .
5. **Sanders GD**, Harris RA, Hlatky MA, Owens DK. Prevention of sudden cardiac death: a probabilistic model for decision support. *Journal of the American Medical Informatics Association* 1995; Annual Supplement 258-262. PubMed PMID: 8563280; PubMed Central PMCID: PMC2579095.
6. **Sanders GD**, Dembitzer AD, Heidenreich PA, McDonald KM, Owens DK. Presentation and explanation of medical decision models using the World Wide Web. *Journal of the American Medical Informatics Association* 1996; Annual Supplement: 60-64. PubMed PMID: 8947628; PubMed Central PMCID: PMC2233151.

7. Owens DK, **Sanders GD**, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, Hlatky MA. Cost effectiveness of implantable cardioverter defibrillators (ICDs) relative to amiodarone for prevention of sudden cardiac death. *Annals of Internal Medicine* 1997; 126: 1-12. PubMed PMID: 8992917.
8. Salpeter SR, **Sanders GD**, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: A risk-benefit and cost-effectiveness analysis. *Annals of Internal Medicine* 1997; 127:1051-1061. PubMed PMID: 9412307.
9. Cheng CHF, **Sanders GD**, McDonald KM, Heidenreich PA, Hlatky MA, Owens DK. Design of a modular, extensible decision support system for arrhythmia therapy. *Journal of the American Medical Informatics Association* 1998; Annual Supplement: 693-697. PubMed PMID: 9929308; PubMed Central PMCID: PMC2232248.
10. Gould MK, Dembitzer AD, **Sanders GD**, Garber AM. Low molecular weight heparins compared with unfractionated heparin for the treatment of acute deep vein thrombosis: A cost-effectiveness analysis. *Annals of Internal Medicine* 1999; 130:789-799. PubMed PMID: 10366368.
11. **Sanders GD**, Hagerty CG, Sonnenberg FA, Hlatky MA, Owens DK. Distributed decision support for using a web-based interface: Prevention of sudden cardiac death. *Medical Decision Making* 1999; 19(2): 157-166. PubMed PMID: 10231078.
12. McConnell LM, **Sanders GD**, Owens DK. Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. *Genetic Testing* 1999; 3(1): 47-53. PubMed PMID: 10464577.
13. **Sanders GD**, Nease RF, Owens, DK. Design and pilot evaluation of a system to develop computer-based site-specific practice guidelines from decision models. *Medical Decision Making* 2000; 20(2): 145-159. (Reprinted in the 2002 IMIA Yearbook of Medical Informatics) PubMed PMID: 10772353.
14. Cheng CHF, **Sanders GD**, Hlatky MA, Heidenreich PA, McDonald KM, Lee BK, Larson MS, Owens DK. Cost effectiveness of radiofrequency ablation for supraventricular tachycardia. *Annals of Internal Medicine* 2000; 133(11): 864-876. Erratum in: *Ann Inter Med* 2001 Nov 20; 135 (10):933. PubMed PMID: 11103056.
15. **Sanders GD**, Nease RF, Owens DK. Publishing web-based guidelines using interactive decision models. *Journal of Evaluation in Clinical Practice*. 2001; 7(2). 175-189. PubMed PMID: 11489042.
16. Barnato AE, **Sanders GD**, Owens DK. Cost effectiveness of a potential vaccine for *Coccidioides immitis* Emerging Infectious Diseases. 2001; 7(5). 797-806. PubMed PMID: 11747691; PubMed Central PMCID: PMC2631863.
17. **Sanders GD**, Hlatky MA, Every NE, McDonald KM, Heidenreich PA, Parsons LS, Owens DK. Cost effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. *Annals of Internal Medicine*. 2001; 135: 870-883. PubMed PMID: 11712877.
18. Groeneveld PW, Kwong JL, Lie Y, Rodriguez AJ, Jones MP, **Sanders GD**, Garber AM. The Cost-Effectiveness of Automated External Defibrillators on U.S. Airlines. *JAMA* 2001; 286(12): 1482-1489. PubMed PMID: 11572741.
19. Sim I, **Sanders GD**, McDonald KM. Evidence-based practice for mere mortals: the role of informatics and health services research. *JGIM* 2002; 17: 302-308. PubMed PMID: 11972727; PubMed Central PMCID: PMC1495037.
20. Haberland CA, Benitz WE, **Sanders GD**, Pietzsch JB, Yamada S, Nguyen L, Garber AM. Perinatal screening of group B strep: Cost-benefit analysis of rapid PCR. *Pediatrics* 2002;110(3):471-80. PubMed PMID: 12205247.
21. Owens DK, **Sanders GD**, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator (ICD). *American Heart Journal* 2002;144(3):440-8.

PubMed PMID: 12228780.

22. **Sanders GD**, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. *Emerging Infectious Diseases* 2003; 9(1): 37-48. PubMed PMID: 12533280; PubMed Central PMCID: PMC2873748.
23. Gould MK, **Sanders GD**, Barnett PG, MacLean CC, Rydzak CE, McClellan MB, Owens DK. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. *Annals of Internal Medicine* 2003 May 6; 138(9): 724-735. PubMed PMID: 12729427.
24. Fowler RA, Hill-Popper M, Petrou C, Stasinou J, **Sanders GD**, Garber AM. Cost-effectiveness of recombinant human activated protein C and the influence of the severity of illness in the treatment of patients with severe sepsis. *Journal of Critical Care* 2003 vol 18(3, September):181-191. PubMed PMID: 14595571.
25. Cantor SB, Fahs MC, Mandelblatt J, Meyers ER, **Sanders GD**. Decision science and cervical cancer. *Cancer* 2003; 98(9 Suppl): 2003-8. PubMed PMID: 14603536.
26. Hlatky MA, **Sanders GD**, Owens DK. Cost-Effectiveness of the Implantable Cardioverter Defibrillator. *Cardiac Electrophysiology Review* 2003; 7(4): 479-82. PubMed PMID: 15071279.
27. Auerbach AD, **Sanders GD**, Hambleton J. Cost-effectiveness of screening for hypercoagulable states in patients with idiopathic deep vein thrombosis. *American Journal of Medicine* 2004; 116:816–828. PubMed PMID: 15178497.
28. Lin OS, Keeffe EB, **Sanders GD**, Owens DK. Cost effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. *Alimentary Pharmacology and Therapeutics* 2004; 19: 1159–1172. PubMed PMID: 15153169.
29. Vij R, Triadafilopoulos G, Kunz P, Owens DK, **Sanders GD**. Cost effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. *Gastrointestinal Endoscopy* 2004; 60(5): 739-756. PubMed PMID: 15557950.
30. **Sanders GD**, Hlatky MA, Owens DK. Special report: cost-effectiveness of implantable cardioverter-defibrillators in a MADIT-II population. *Technol Eval Cent Asses Program Exec Summ* 2004;19(3):1-2.
31. Taira AV, Neukermans CP, **Sanders GD**. Evaluating Human Papillomavirus Vaccination Programs. *Emerging Infectious Diseases* 2004; 10(11): 1915-1923. PubMed PMID: 15550200; PubMed Central PMCID: PMC3328990.
32. Hlatky MA, **Sanders GD**, Owens DK. Evidence-Based Medicine and Policy: The case of the Implantable Cardioverter Defibrillator. *Health Affairs* 2005; 24(1): 42-51. PubMed PMID: 15647214.
33. **Sanders GD**, Bayoumi AM, Sundaram S, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK. Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy. *New England Journal of Medicine* 2005; 352(6): 570-585. PubMed PMID: 15703422.
34. Fowler RA, **Sanders GD**, Bravata DM, Nouri B, Gastwirth JM, Peterson D, Broker AG, Garber AM, Owens DK. Cost effectiveness of defending against bioterrorism a comparison of vaccination and antibiotic prophylaxis for anthrax in urban populations at risk against bioterror attacks. *Annals of Internal Medicine* 2005; 142(8) :601-610. PubMed PMID: 15838066.
35. Al-Khatib SM, **Sanders GD**, Mark DB, Lee KL, Bardy GH, Bigger JT, Buxton AE, Connolly S, Kadisj A, Moss A, Feldman AM, Ellenbogen KA, Singh S, Califf RM. Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy In Patients With Left Ventricular Dysfunction: Randomized Trial Evidence Through 2004. *American Heart Journal* 2005; 149(6): 1020-1034. PubMed PMID: 15976783.

36. **Sanders GD**, Hlatky MA, Owens DK. Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Preventing Sudden Death. *New England Journal of Medicine* 2005 353(14): 1471-80. PubMed PMID: 15838066.
37. Hlatky MA, **Sanders GD**, Owens DK. Cost-Effectiveness as an Outcome in Randomized Clinical Trials. *Clinical Trials* 2006;3(6):543-51. PubMed PMID: 17170039.
38. Long EF, Brandeau ML, Glavin CM, Vinichenko TN, Tole SP, Schwartz A, **Sanders GD**, Owens DK. Effectiveness and Cost Effectiveness of Strategies to Expand Antiretroviral Therapy in St Petersburg Russia, *AIDS* 2006; 20(17): 2207-2215. PubMed PMID: 17086061.
39. Matchar DB, Mark DB, Patel MR, Hurwitz LM, Orlando LA, McCrory DC, **Sanders GD**. Non-Invasive Imaging for Coronary Artery Disease [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Oct 03. Available from <http://www.ncbi.nlm.nih.gov/books/NBK263429/> PubMed PMID: 25520987.
40. Myers ER, Havrilesky LJ, Kulasingam SL, **Sanders GD**, Cline KE, Gray RN, Berchuck A, McCrory DC. Genomic tests for ovarian cancer detection and management. *Evd Rep Technol Assess (Full Rep)*. 2006 Oct;(145):1-100. PubMed PMID: 17764207.
41. Perlroth DJ, **Sanders GD**, Gould MK. Effectiveness and Cost Effectiveness of Thrombolysis in Submassive Pulmonary Embolism. *Archives of Internal Medicine* 2007;167:74-80. PubMed PMID: 17210881.
42. Patel MR, Hurwitz LM, Orlando L, McCrory DC, **Sanders GD**, Matchar DB, Mark D. Noninvasive imaging for coronary artery disease: a technology assessment for the Medicare Coverage Advisory Commission. *Am Heart J* 2007;153(2):161-74. PubMed PMID: 17239673.
43. Owens DK, Sundaram V, Lazzeroni LC, Douglass LR, Tempio P, Holodniy M, **Sanders GD**, Shadle VM, McWhorter VA, Agoncillo T, Haren N, Chavis D, Borowsky LH, Yano EM, Jensen P, Simberkoff M, Bozzette BA. HIV testing of at risk patients in a large integrated health care system. *J Gen Intern Med*. 2007;22(3):315-20. PubMed PMID: 17356961; PubMed Central PMCID: PMC1824727.
44. Al-Khatib SM, **Sanders GD**, Bigger JT, Buxton AE, Califf RM, Carlson M, Curtis A, Curtis J, Fair E, Gersh BJ, Gold MR, Haghghi-Mood A, Hammill SC, Healey J, Hlatky MA, Hohnloser S, Kim RJ, Lee K, Mark DB, Mianulli M, Mitchell B, Prystowsky EN, Smith J, Steinhaus D, Zareba W. Preventing Tomorrow's Sudden Cardiac Death Today Part I: Current Data on Risk Stratification for Sudden Cardiac Death. *Am Heart J* 2007 153(6):941-50. PubMed PMID: 17540194.
45. **Sanders GD**, Al-Khatib SM, Berliner E, Bigger JT, Buxton AE, Califf RM, Carlson M, Curtis AB, Curtis JP, Domanski M, Fain E, Gersh BJ, Gold MR, Goldberger J, Haghghi-Mood A, Hammill SC, Harder J, Healey J, Hlatky MA, Hohnloser SH, Lee K, Mark DB, Mitchell B, Phurrough S, Prystowsky E, Smith JM, Stockbridge N, Temple R. Preventing Tomorrow's Sudden Cardiac Death Today: Part II: Translating Sudden Cardiac Death Risk Assessment Strategies into Practice and Policy. *Am Heart J* 2007 153(6):951-9. PubMed PMID: 17540195.
46. Cox CE, Carson SS, Govert JA, Chelluri L, **Sanders GD**. Economic evaluation of prolonged mechanical ventilation. *Crit Care Med*. 2007. 35(8):1918-1927. PubMed PMID: 17581479; PubMed Central PMCID: PMC2745076.
47. Owens DK, Sundaram V, Lazzeroni LC, Douglass LR, **Sanders GD**, Taylor K, VanGroningen R, Shadle VM, McWhorter VC, Agoncillo T, Haren N, Nyland J, Tempio P, Khayr W, Dietzen DJ, Jensen P, Simberkoff MS, Bozzette SA, Holodniy M. Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV. *Am J Public Health*. Dec 2007;97(12):2173-2178. Epub 2007 Oct 30. PubMed PMID: 17971545; PubMed Central PMCID: PMC2089082.

48. Dosiou C, **Sanders GD**, Araki SS, Crapo LM. Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. *Eur J Endocrinol*. Jun 2008;158(6):841-851. PubMed PMID: 18505905.
49. Anaya HD, Hoang T, Golden JF, Goetz MB, Gifford A, Bowman C, Osborn T, Owens DK, **Sanders GD**, Asch SM. Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testing. *J Gen Intern Med*. Jun 2008;23(6):800-807. Epub 2008 Apr 18. PubMed PMID: 18421508; PubMed Central PMCID: PMC2517869.
50. Schultz EM, **Sanders GD**, Trotter PR, Patz EF, Jr., Silvestri GA, Owens DK, Gould MK. Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. *Thorax*. 2008;63(4):335-41. Epub 2007 Oct 26. PubMed PMID: 17965070; PubMed Central PMCID: PMC2882437.
51. **Sanders GD**, Bayoumi AM, Holodniy M, Owens DK. Cost-effectiveness of HIV screening in patients older than 55 years of age. *Ann Intern Med*. Jun 17 2008;148(12):889-9038. PubMed PMID: 18559840; PubMed Central PMCID: PMC3428219.
52. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, **Sanders GD**, Owens DK. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: A South African analysis. *Arch Intern Med*. Sep 22 2008;168(17):1910-1918. PubMed PMID: 18809819; PubMed Central PMCID: PMC2894578.
53. Havrilesky L, **Sanders GD**, Kulasingam S, Myers ER. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? *Gynecologic Oncology* Nov 2008;111(2):179-187. Epub 2008 Aug 21. PubMed PMID: 18722004.
54. Al-Khatib SM, **Sanders GD**, Carlson M, Cicic A, Curtis A, Fonarow GC, Groeneveld PW, Hayes D, Heidenreich P, Mark D, Peterson E, Prystowsky EN, Sager P, Thomas K, Yancy X, Zareba W, Zipes D. Preventing tomorrow's sudden cardiac death today: Dissemination of effective therapies for sudden cardiac death prevention. *American Heart Journal* 2008;156(4):613-622. Epub 2008 July 26. PubMed PMID: 18926144.
55. Tole SP, **Sanders GD**, Bayoumi AM, Galvin CM, Vinichenko TN, Brandeau ML, Owens DK. Cost-effectiveness of voluntary HIV screening strategies in Russia. *International Journal of STD & AIDS* Jan 2009;20(1):46-51. PubMed PMID: 19103893; PubMed Central PMCID: PMC2981087.
56. Holland DP, **Sanders GD**, Dukes-Hamilton C, Stout JE. Costs and Cost Effectiveness of Four Treatment Regimens for Latent Tuberculosis Infection. *American Journal of Respiratory and Critical Care Medicine* 2009 Jun 1;179(11):1055-60. Epub 2009 Mar 19. PubMed PMID: 19299495; PubMed Central PMCID: PMC2689913.
57. Sundaram V, Lazzeroni LC, Douglass LR, **Sanders GD**, Tempio P, Owens DK. A Randomized Trial of Computer-Based Reminders and Audit and Feedback to Improve HIV Screening in a Primary Care Setting. *Int J STD AIDS* 2009 Aug;20(8):527-33. PubMed PMID: 19625582.
58. **Sanders GD**, Inoue L, Samsa G, Kulasingam S, Matchar D. Use of Bayesian Techniques in Randomized Clinical Trials: A CMS Case Study [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2009 Sep 18. Available from <http://www.ncbi.nlm.nih.gov/books/NBK253213/> PubMed PMID: 25392890.
59. Piccini J Al-Khatib S, Myers E, Anstrom K, Buxton A, Peterson E, **Sanders GD**. Optimal Timing of Implantable Cardioverter-Defibrillator Implantation after Myocardial Infarction: A Decision Analysis. *J Cardiovasc Electrophysiol*. 2010 Jul;21(7):791-8. Epub 2010 Feb 1. PubMed PMID: 20132397.
60. Al-Khatib S, Piccini J, Knight, D, Stewart M, Clapp-Channing N, **Sanders GD**. Remote Monitoring of Implantable Cardioverter Defibrillators versus Quarterly Device Interrogations in Clinic: Results from a Randomized Pilot Clinical Trial. *J Cardiovasc Electrophysiol*. 2010 May;21(5):545-50. Epub 2009 Dec 15. PubMed PMID: 20021522.

61. **Sanders GD**, Anaya HD, Asch S, Hoang T, Golden JF, Bayoumi AM, Owens DK. Cost-Effectiveness of Strategies to Improve HIV Testing and Receipt of Results: Economic Analysis of a Randomized Controlled Trial. *J Gen Intern Med* 2010; 25(6):556-63. Epub 2010 Mar 4. PubMed PMID: 20204538. PubMed Central PMCID: PMC2869414.
62. **Sanders GD**, Kong MH, Al-Khatib SM, Peterson ED. Cost Effectiveness of Implantable Cardioverter Defibrillators in Patients ≥ 65 Years of Age. *Am Heart J*. 2010 Jul;160(1):122-31. PubMed PMID: 20598982.
63. Kong MH, Peterson ED, Fonarow GC, **Sanders GD**, Yancy CW, Russo AM, Curtis AB, Sears SF Jr, Thomas KL, Campbell S, Carlson MD, Chiamis C, Cook NL, Hayes DL, LaRue M, Hernandez AF, Lyons EL, Al-Khatib SM. Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies. *Am Heart J*. 2010 Oct;160(4):605-18. PubMed PMID: 20934553. PubMed Central PMCID: PMC2956019.
64. **Sanders GD**, Powers B, Crowley M, Myers E, McBroom A, Musty M, Gray R. Future Research Needs for Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease: Identification of Future Research Needs from Comparative Effectiveness Review No. 18 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Nov. Available from <http://www.ncbi.nlm.nih.gov/books/NBK51296/> PubMed PMID: 21433330.
65. Holland DP, **Sanders GD**, Hamilton CD, Stout JE. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. *PLoS One*. 2011;6(7):e22276. Epub 2011 Jul 18. PubMed PMID: 21789248; PubMed Central PMCID: PMC3138781.
66. Havrilesky LJ, **Sanders GD**, Kulasingam S, Chino JP, Berchuk A, Marks JR, Myers ER. Development of an Ovarian Cancer Screening Decision Model that Incorporates Disease Heterogeneity: Implications for Potential Mortality Reduction. *Cancer*. 2011 Feb 1;117(3):545-53. Epub 2010 Dec 13. PubMed PMID: 21254049.
67. Kong MH, Al-Khatib SM, **Sanders GD**, Hasselblad V, Peterson ED. Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis. *Cardiol J*. 2011;18(5):503-14. Review. PubMed PMID: 21947985.
68. Al-Khatib SM, **Sanders GD**, O'Brien SO, Matlock D, Zimmer LO, Masoudi FA, Peterson E. Do Physicians' Attitudes Toward Implantable Cardioverter Defibrillator Therapy Vary by Patient Age, Gender or Race? *Ann Noninvasive Electrocardiol*. 2011 Jan;16(1):77-84. PubMed PMID: 21251138.
69. Kong MH, Fonarow GC, Peterson ED, Curtis AB, Hernandez AF, **Sanders GD**, Thomas KL, Hayes DL, Al-Khatib SM. Systematic review of the incidence of sudden cardiac death in the United States. *J Am Coll Cardiol*. 2011 Feb 15;57(7):794-801. PubMed PMID: 21310315.
70. Al-Khatib SM, Hellkamp A, Curtis J, Mark D, Peterson E, **Sanders GD**, Heidenreich PA, Hernandez AF, Curtis LH, Hammill S. Non-evidence-based ICD implantations in the United States. *JAMA*. 2011 Jan 5;305(1):43-9. PubMed PMID: 21205965. PubMed Central PMCID: PMC3432303.
71. Matlock DD, Kutner JS, Emsermann CB, Al-Khatib SM, **Sanders GD**, Dickinson LM, Rumsfeld JS, Davidson AJ, Crane LA, Masoudi FA. Regional variations in physicians' attitudes and recommendations surrounding implantable cardioverter-defibrillators. *J Card Fail*. 2011 Apr;17(4):318-24. Epub 2011 Feb 22. PubMed PMID: 21440870.
72. **Sanders GD**, Coeytaux R, Dolor RJ, Hasselblad V, Patel UD, Powers B, Yancy WS, Gray RN, Irvine RJ, Kendrick A. Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Jun. Available from <http://www.ncbi.nlm.nih.gov/books/NBK61789/> PubMed PMID: 21977520.

73. Myers E, **Sanders GD**, Ravi D, Matchar D, Havrilesky L, Samsa G, Powers B, McBroom A, Musty M, Gray R. Evaluating the Potential Use of Modeling and Value-of-Information Analysis for Future Research Prioritization Within the Evidence-Based Practice Center Program [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Jun. Available from <http://www.ncbi.nlm.nih.gov/books/NBK62134/> PubMed PMID: 21977527.
74. Eapen ZJ, Peterson ED, Fonarow GC, **Sanders GD**, Yancy CW, Sears SF Jr, Carlson MD, Curtis AB, Hall LL, Hayes DL, Hernandez AF, Mirro M, Prystowsky E, Russo AM, Thomas KL, Al-Khatib SM. Quality of care for sudden cardiac arrest: Proposed steps to improve the translation of evidence into practice. *Am Heart J*. 2011 Aug;162(2):222-31. Epub 2011 Jul 7. Review. PubMed PMID: 21835281.
75. Kemper AR, Coeytaux R, **Sanders GD**, Van Mater H, Williams JW, Gray RN, Irvine RJ, Kendrick A. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Sep. Available from <http://www.ncbi.nlm.nih.gov/books/NBK65169/> PubMed PMID: 22091470.
76. Van Mater HA, Williams JW, Coeytaux RR, **Sanders GD**, Kemper AR. Psychometric characteristics of outcome measures in juvenile idiopathic arthritis: A systematic review. *Arthritis Care Res (Hoboken)*. 2011 Oct 17. doi: 10.1002/acr.20667. [Epub ahead of print] PubMed PMID: 22006870.
77. Powers BJ, Coeytaux RR, Dolor RJ, Hasselblad V, Patel UD, Yancy WS Jr, Gray RN, Irvine RJ, Kendrick AS, **Sanders GD**. Updated Report on Comparative Effectiveness of ACE inhibitors, ARBs, and Direct Renin Inhibitors for Patients with Essential Hypertension: Much More Data, Little New Information. *J Gen Intern Med*. 2011 Dec 7. [Epub ahead of print] PubMed PMID: 22147122. PubMed Central PMCID: PMC3358398.
78. Holland DP, **Sanders GD**, Hamilton CD, Stout JE. Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. *PLoS One*. 2012;7(1):e30194. Epub 2012 Jan 17. PubMed PMID: 22272302; PubMed Central PMCID: PMC3260212.
79. Kemper AR, Van Mater HA, Coeytaux RR, Williams JW Jr, **Sanders GD**. Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. *BMC Pediatr*. 2012 Mar 15;12:29. PubMed PMID: 22420649. PubMed Central PMCID: PMC3340294.
80. Powers BJ, Crowley MJ, McCrory DC, Pendergast K, Posey R, Hadley C, Gray R, **Sanders GD**. Future Research Needs for Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRIs) for Treating Hypertension: Identification of Future Research Needs From Comparative Effectiveness Review No. 34 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Mar. Available from <http://www.ncbi.nlm.nih.gov/books/NBK84673/>. PubMed PMID: 22439161.
81. Pun PH, Schumm D, **Sanders GD**, Hickey D, Middleton JP, Clapp-Channing N, Al-Khatib SM. A pilot study using an implantable device to characterize cardiac arrhythmias in hemodialysis patients: implications for future research. *Ann Noninvasive Electrocardiol*. 2012 Apr;17(2):159. PubMed PMID: 22537338.
82. Crowley MJ, Powers BJ, Myers ER, McBroom AJ, **Sanders GD**. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization. *Am Heart J*. 2012 May;163(5):777-782.e8. PubMed PMID: 22607854.
83. Carey TS, **Sanders GD**, Viswanathan M, Trikalinos TA, Kato E, Chang S. Framework for Considering Study Designs for Future Research Needs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Mar. Available from <http://www.ncbi.nlm.nih.gov/books/NBK95273/>. PubMed PMID: 22624168.
84. Lobach D, **Sanders GD**, Bright TJ, Wong A, Dhurjati R, Bristow E, Bastian L, Coeytaux R, Samsa G, Hasselblad V, Williams JW, Wing L, Musty M, Kendrick AS. Enabling health care decision making through clinical decision support and knowledge management. *Evid Rep Technol Assess (Full Rep)*. 2012 Apr;(203):1-784. Review. PubMed PMID: 23126650.

85. Williams JW, Cox CE, Hargett CW, Gilstrap DL, Castillo CE, Govert JA, Lugogo NL, Coeytaux RR, McCrory DC, Hasselblad V, McBroom AJ, Posey R, Gray R, **Sanders GD**. Noninvasive Positive-Pressure Ventilation (NPPV) for Acute Respiratory Failure [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jul. Available from <http://www.ncbi.nlm.nih.gov/books/NBK99179/> PubMed PMID: 22876372.
86. Dolor RJ, Patel MR, Melloni C, Chatterjee R, McBroom AJ, Musty MD, Wing L, Coeytaux RR, Ross AK, Bastian LA, Anderson M, Kosinski AS, **Sanders GD**. Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jun. Available from <http://www.ncbi.nlm.nih.gov/books/NBK98721/> PubMed PMID: 22812020.
87. Bright TJ, Wong A, Dhurjati R, Bristow E, Bastian L, Coeytaux RR, Samsa G, Hasselblad V, Williams JW, Musty MD, Wing L, Kendrick AS, **Sanders GD**, Lobach D. Effect of clinical decision-support systems: a systematic review. *Ann Intern Med*. 2012 Jul 3;157(1):29-43. Review. PubMed PMID: 22751758.
88. Chang SM, Carey T, Kato EU, Guise JM, **Sanders GD**. Identifying Research Needs for Improving Health Care. *Ann Intern Med*. 2012 Jul 31. doi: 10.7326/0003-4819-157-6-201209180-00515. [Epub ahead of print] PubMed PMID: 22847017.
89. Atwater BD, Dai D, Allen-Lapointe NM, Al-Khatib SM, Zimmer LO, **Sanders GD**, Peterson ED. Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. *Am Heart J*. 2012 Nov;164(5):750-755.e1. doi: 10.1016/j.ahj.2012.08.002. Epub 2012 Oct 16. PubMed PMID: 23137506.
90. Leisy PJ, Coeytaux RR, Wagner GS, Chung EH, McBroom AJ, Green CL, Williams JW Jr, **Sanders GD**. ECG-based signal analysis technologies for evaluating patients with acute coronary syndrome: A systematic review. *J Electrocardiol*. 2012 Dec 26. doi:pii: S0022-0736(12)00481-5. 10.1016/j.jelectrocard.2012.11.010. [Epub ahead of print] PubMed PMID: 23273746.
91. Coeytaux RR, Leisy PJ, Wagner GS, McBroom AJ, Green CL, Wing L, Irvine RJ, **Sanders GD**. Systematic Review of ECG-based Signal Analysis Technologies for Evaluating Patients With Acute Coronary Syndrome [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jun. Available from <http://www.ncbi.nlm.nih.gov/books/NBK280225/>
92. McCrory DC, Coeytaux RR, Yancy WS, Schmit KM, Kemper AR, Goode A, Hasselblad V, Heidenfelder BL, Irvine RJ, Musty MD, Gray R, **Sanders GD**. Assessment and Management of Chronic Cough [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Jan. Available from <http://www.ncbi.nlm.nih.gov/books/NBK116707/> PubMed PMID: 23367526.
93. **Sanders GD**, Patel MR, Chatterjee R, Ross AK, Bastian LA, Coeytaux RR, Heidenfelder BL, Musty MD, Dolor RJ. Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 58 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Feb. Available from <http://www.ncbi.nlm.nih.gov/books/NBK153207/> PubMed PMID: 23905197.
94. Dolor RJ, Patel MR, Melloni C, Chatterjee R, Heidenfelder BL, Musty MD, Chobot M, Irvine RJ, **Sanders GD**. Treatment Strategies for Women With Coronary Artery Disease: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 66 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Feb. Available from <http://www.ncbi.nlm.nih.gov/books/NBK148780/> PubMed PMID: 23865095.
95. Hess PL, Laird A, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Hall WJ, Steinman R, Dorian P, Al Hallstrom PD, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Al-Khatib SM, Piccini JP, Inoue LY, **Sanders GD**. Survival Benefit of Primary Prevention Implantable Cardioverter-Defibrillator Therapy After Myocardial Infarction: Does Time to Implant Matter? A Meta-Analysis Using Patient-Level Data from 4 Clinical Trials. *Heart Rhythm*. 2013 Feb 13. doi:pii: S1547-5271(13)00118-5. 10.1016/j.hrthm.2013.02.011. [Epub ahead of print] PubMed PMID: 23416381.

96. Crowley MJ, Powers BJ, Myers ER, McCrory DC, McBroom AJ, **Sanders GD**. Angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers: do future research needs differ across disease states? *Comparative Effectiveness Research* 2013;3 1–9.
97. Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, Anstrom KJ, Curtis J, Al-Khalidi H, Curtis LH, Heidenreich P, Peterson ED, **Sanders G**, Clapp-Channing N, Lee KL, Moss AJ. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. *JAMA*. 2013 Jan 2;309(1):55-62. doi: 10.1001/jama.2012.157182. PubMed PMID: 23280225; PubMed Central PMCID: PMC3638257.
98. Eapen ZJ, McBroom AJ, Gray R, Musty MD, Hadley C, Hernandez AF, **Sanders GD**. Priorities for Comparative Effectiveness Reviews in Cardiovascular Disease. *Circ Cardiovasc Qual Outcomes* 2013 Mar 1;6(2):139-47.
99. Al-Khatib SM, Fonarow GC, Hayes DL, Curtis AB, Sears SF, **Sanders GD**, Hernandez AF, Mirro MJ, Thomas KL, Eapen ZJ, Russo AM, Yancy CW. Performance measures to promote quality improvement in sudden cardiac arrest prevention and treatment. *Am Heart J* 2013 Jun;165(6):862-8
100. Hazelton AG, Al-Khatib SM, Fonarow GC, Thomas KL, Hayes D, **Sanders GD**, Campbell S, Yancy C, Peterson ED, Sears S. Assessment of the Quality of Existing Patient Education Tools Focused on Sudden Cardiac Arrest: A Systematic Evaluation by the Sudden Cardiac Arrest Thought Leadership Alliance (SCATLA). *Patient Preference and Adherence* 2013 Apr 26;7:361-8
101. Jones WS, Schmit KM, Vemulapalli S, Subherwal S, Patel MR, Hasselblad V, Heidenfelder BL, Chobot MM, Posey R, Wing L, **Sanders GD**, Dolor RJ. Treatment Strategies for Patients With Peripheral Artery Disease [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 May. Available from <http://www.ncbi.nlm.nih.gov/books/NBK148574/> PubMed PMID: 23844447.
102. Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Urrutia RP, Lowery WJ, Dinan M, McBroom AJ, Wing L, Musty MD, Lallinger KR, Hasselblad V, **Sanders GD**, Myers ER. Oral contraceptive use for the primary prevention of ovarian cancer. *Evid Rep Technol Assess (Full Rep)*. 2013 Jun;(212):1-514. Review. PubMed PMID: 24423062.
103. Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, **Sanders GD**, Myers ER. Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer: A Systematic Review and Meta-Analysis. *Obstetrics & Gynecology*. 2013 Jul;122(1):139-147
104. Myers ER, Aubuchon-Endsley N, Bastian LA, Gierisch JM, Kemper AR, Swamy GK, Wald MF, McBroom AJ, Lallinger KR, Gray RN, Green C, **Sanders GD**. Efficacy and Safety of Screening for Postpartum Depression [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Apr. Available from <http://www.ncbi.nlm.nih.gov/books/NBK137724/> PubMed PMID: 23678510.
105. Lopes RD, Crowley MJ, Shah BR, Melloni C, Wood KA, Chatterjee R, Povsic TJ, Dupre ME, Kong DF, de Barros e Silva PGM, dos Santos MHH, Armaganijan LV, Katz M, Kosinski A, McBroom AJ, Chobot MM, Gray R, **Sanders GD**. Stroke Prevention in Atrial Fibrillation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Aug. Available from <http://www.ncbi.nlm.nih.gov/books/NBK159054/> PubMed PMID: 24049843.
106. Al-Khatib SM, Lapointe NA, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, Povsic TJ, Raju SS, Shah BR, Kosinski A, McBroom AJ, Chobot MM, Gray R, **Sanders GD**. Treatment of Atrial Fibrillation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Jun. Available from <http://www.ncbi.nlm.nih.gov/books/NBK153118/> PubMed PMID: 23905191.
107. Allen LaPointe NM, Lokhnygina Y, **Sanders GD**, Peterson ED, Al-Khatib SM. Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. *Am Heart J*. 2013 Nov;166(5):871-8. doi:

10.1016/j.ahj.2013.08.010. Epub 2013 Sep 24. PubMed PMID: 24176443; PubMed Central PMCID: PMC3818098.

108. Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, **Sanders GD**, Myers ER. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. *J Clin Oncol*. 2013 Nov 20;31(33):4188-98. doi: 10.1200/JCO.2013.48.9021. Epub 2013 Oct 21. Review. PubMed PMID: 24145348.
109. Balekian AA, Silvestri GA, Simkovich SM, Mestaz PJ, **Sanders GD**, Daniel J, Porcel J, Gould MK. Accuracy of clinicians and models for estimating the probability that a pulmonary nodule is malignant. *Ann Am Thorac Soc*. 2013 Dec;10(6):629-35. doi: 10.1513/AnnalsATS.201305-107OC. PubMed PMID: 24063427; PubMed Central PMCID: PMC3960964.
110. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, McBroom AJ, Hasselblad V, **Sanders GD**, Myers ER. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. *Cancer Epidemiol Biomarkers Prev*. 2013 Nov;22(11):1931-43. doi: 10.1158/1055-9965.EPI-13-0298. Epub 2013 Sep 6. Review. PubMed PMID: 24014598.
111. Peragallo Urrutia R, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, Hasselblad V, **Sanders GD**, Myers ER. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. *Obstet Gynecol*. 2013 Aug;122(2 Pt 1):380-9. doi: 10.1097/AOG.0b013e3182994c43. Review. PubMed PMID: 23969809.
112. Yancy WS Jr, McCrory DC, Coeytaux RR, Schmit KM, Kemper AR, Goode A, Hasselblad V, Heidenfelder BL, **Sanders GD**. Efficacy and tolerability of treatments for chronic cough: a systematic review and meta-analysis. *Chest*. 2013 Dec;144(6):1827-38. doi: 10.1378/chest.13-0490. Review. PubMed PMID: 23928798.
113. Schmit KM, Coeytaux RR, Goode AP, McCrory DC, Yancy WS Jr, Kemper AR, Hasselblad V, Heidenfelder BL, **Sanders GD**. Evaluating cough assessment tools: a systematic review. *Chest*. 2013 Dec;144(6):1819-26. doi: 10.1378/chest.13-0310. Review. PubMed PMID: 23928647.
114. Bayoumi AM, Barnett PG, Joyce VR, Griffin SC, Sun H, Bansback NJ, Holodniy M, **Sanders G**, Brown ST, Kyriakides TC, Angus B, Cameron DW, Anis AH, Sculpher M, Owens DK. Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. *J Acquir Immune Defic Syndr*. 2013 Dec 1;64(4):382-91.
115. Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LY, **Sanders GD**. Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator? *Int J Cardiol*. 2014 Mar 1;172(1):253-4. doi: 10.1016/j.ijcard.2013.12.278. Epub 2014 Jan 10. PubMed PMID: 24467982.
116. Pun PH, Hellkamp AS, **Sanders GD**, Middleton JP, Hammill SC, Al-Khalidi HR, Curtis LH, Fonarow GC, Al-Khatib SM. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. *Nephrol Dial Transplant*. 2014 Nov 17. pii: gfu274. [Epub ahead of print] PubMed PMID: 25404241.
117. Allen LaPointe NM, Lokhnygina Y, Rimmler J, **Sanders GD**, Peterson ED, Al-Khatib SM. Use Of Rate And Rhythm Control Drugs In Patients Younger Than 65 Years With Atrial Fibrillation. *J Atr Fibrillation*. 2014;7(1):22-30. PubMed PMID: 25530826; PubMed Central PMCID: PMC4269378.
118. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, Povsic TJ, Raju SS, Shah B, Kosinski AS, McBroom AJ, **Sanders GD**. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. *Ann Intern Med*. 2014 Jun 3;160(11):760-73. doi: 10.7326/M13-1467. Review. PubMed PMID: 24887617.

119. Al-Khatib SM, Hellkamp AS, Fonarow GC, Mark DB, Curtis LH, Hernandez AF, Anstrom KJ, Peterson ED, **Sanders GD**, Al-Khalidi HR, Hammill BG, Heidenreich PA, Hammill SC. Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. *JAMA*. 2014 Jun 4;311(21):2209-15. doi: 10.1001/jama.2014.5310. PubMed PMID: 24893088; PubMed Central PMCID: PMC4122230.
120. Pun PH, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Hess PL, Inoue LY, **Sanders GD**. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. *Am J Kidney Dis*. 2014 Jul;64(1):32-9. doi: 10.1053/j.ajkd.2013.12.009. Epub 2014 Feb 8. PubMed PMID: 24518128.
121. Crowley MJ, McCrory DC, Chatterjee R, Gierisch JM, Myers ER, Schmit KM, Coeytaux RR, Correll CU, Kendrick AS, **Sanders GD**. Prioritization of research addressing antipsychotics for adolescents and young adults with bipolar disorder. *Ann Intern Med*. 2014 Apr 1;160(7):492-8. doi: 10.7326/M13-2549. PubMed PMID: 24567115.
122. Gierisch JM, Myers ER, Schmit KM, McCrory DC, Coeytaux RR, Crowley MJ, Chatterjee R, Kendrick AS, **Sanders GD**. Prioritization of patient-centered comparative effectiveness research for osteoarthritis. *Ann Intern Med*. 2014 Jun 17;160(12):836-41. doi: 10.7326/M14-0318. PubMed PMID: 24821227.
123. Gierisch JM, Myers ER, Schmit KM, Crowley MJ, McCrory DC, Chatterjee R, Coeytaux RR, Kendrick A, **Sanders GD**. Prioritization of research addressing management strategies for ductal carcinoma in situ. *Ann Intern Med*. 2014 Apr 1;160(7):484-91. doi: 10.7326/M13-2548. PubMed PMID: 24567146.
124. Zeitler EP, Hellkamp AS, Fonarow GC, Hammill SC, Curtis LH, Hernandez AF, Al-Khalidi HR, Curtis JP, Heidenreich PA, Anstrom KJ, Peterson ED, Mark DB, Hammill BG, **Sanders GD**, Al-Khatib SM. Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. *JACC Heart Fail*. 2014 Nov 5. pii: S2213-1779(14)00448-X. doi: 10.1016/j.jchf.2014.09.006. [Epub ahead of print] PubMed PMID: 25543969.
125. Gracieux J, **Sanders GD**, Pokorney SD, Lopes RD, Thomas K, Al-Khatib SM. Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: A systematic review. *Int J Cardiol*. 2014 Oct 5;177(3):990-994. doi: 10.1016/j.ijcard.2014.09.170. [Epub ahead of print] PubMed PMID: 25449512.
126. Steinberg BA, Al-Khatib SM, Edwards R, Han J, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LY, **Sanders GD**. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. *JACC Heart Fail*. 2014 Dec;2(6):623-9. doi: 10.1016/j.jchf.2014.06.007. Epub 2014 Oct 8. PubMed PMID: 25306452; PubMed Central PMCID: PMC4256119.
127. Hess PL, Hellkamp AS, Peterson ED, **Sanders GD**, Al-Khalidi HR, Curtis LH, Hammill BG, Pun PH, Curtis JP, Anstrom KJ, Hammill SC, Al-Khatib SM. Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. *Circ Arrhythm Electrophysiol*. 2014 Oct;7(5):793-9. doi: 10.1161/CIRCEP.114.001455. Epub 2014 Jul 18. PubMed PMID: 25038119; PubMed Central PMCID: PMC4206571.
128. **Sanders GD**, Owens DK, Hlatky MA. Potential Cost-effectiveness of Wearable Cardioverter-Defibrillator Early Post Myocardial Infarction. *Journal of Innovations in Cardiac Rhythm Management*. 2015 (6): 1929-1940.
129. Zeitler EP, Patel D, Hasselblad V, **Sanders GD**, Al-Khatib SM. Complications from prophylactic replacement of cardiac implantable electronic device generators in response to United States Food and Drug Administration recall: A systematic review and meta-analysis. *Heart Rhythm*. 2015 Jul;12(7):1558-64.

130. Skelly A, Hashimoto R, Al-Khatib S, **Sanders-Schmidler G**, Fu R, Brodt E, McDonagh M. Catheter Ablation for Treatment of Atrial Fibrillation. Technology Assessment. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. HHSA 290-2012-00014-I.) AHRQ Publication. Rockville, MD: Agency for Healthcare Research and Quality; April 2015.
131. Al-Khatib SM, Gierisch JM, Crowley MJ, Coeytaux RR, Myers ER, Kendrick A, **Sanders GD**. Future Research Prioritization: Implantable Cardioverter-Defibrillator Therapy in Older Patients. *J Gen Intern Med*. 2015 May 27. [Epub ahead of print] PubMed PMID: 26014894.
132. Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghatge S, Davidson B, Montgomery RC, Crowley MJ, McCrory DC, Kendrick A, **Sanders GD**. Benefits and Harms of Breast Cancer Screening: A Systematic Review. *JAMA*. 2015 Oct 20;314(15):1615-34. PubMed PMID: 26501537
133. Zeitler EP, Hellkamp AS, Schulte PJ, Fonarow GC, Hernandez AF, Peterson ED, **Sanders GD**, Yancy CW, Al-Khatib SM. Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. *Circ Heart Fail*. 2016 Jan;9(1):e002630. doi: 10.1161/CIRCHEARTFAILURE.115.002630. PubMed PMID: 26758365; PubMed Central PMCID: PMC4712727.
134. Gayer CC, Crowley MJ, Lawrence WF, Gierisch JM, Gaglio B, Williams JW Jr, Myers ER, Kendrick A, Slutsky J, **Sanders GD**. An overview and discussion of the Patient-Centered Outcomes Research Institute's decision aid portfolio. *J Comp Eff Res*. 2016 Jul;5(4):407-15. doi: 10.2217/ce-2016-0002. PubMed PMID: 27298206.
135. **Sanders GD**, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *JAMA*. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195. Erratum in: *JAMA*. 2016 Nov 8;316(18):1924. PubMed PMID: 27623463.
136. Neumann PJ, **Sanders GD**. Cost-Effectiveness Analysis 2.0. *N Engl J Med*. 2017 Jan 19;376(3):203-205. doi: 10.1056/NEJMp1612619. PubMed PMID: 28099837.
137. Pun PH, Sheng S, **Sanders GD**, DeVore AD, Friedman D, Fonarow GC, Heidenreich PA, Yancy CW, Hernandez AF, Al-Khatib SM. Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function, *The American Journal of Cardiology*, Volume 119, Issue 6, 15 March 2017, Pages 886-892
138. Sorenson C, Lauezzari G, Daniel G, Burkholder R, Boutin M, Pezalla E, **Sanders G**, McClellan M. Advancing Value Assessment in the United States: A Multistakeholder Perspective. *Value in Health* 20 (2017): 299-307.
139. Al-Khatib SM, Fonarow GC, Joglar JA, Inoue LYT, Mark DB, Lee KL, Kadish A, Bardy G, **Sanders GD**. Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis. *JAMA Cardiology*. Published online March 29, 2017. doi:10.1001/jamacardio.2017.0630

Books and Book Chapters

1. Dong W, Krumholz H, Peterson E, **Sanders GD**, Tavriss D. *Analysis and Interpretation of Registry Data to Evaluate Outcomes* in Gliklich RE, Dreyer NA, eds. *Registries for Evaluating Patient Outcomes: A User's Guide*. (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under Contract No. HHSA29020050035I TO1.)
2. Dong W, Krumholz H, Peterson E, **Sanders GD**, Tavriss D. *Registries for Evaluating Patient Outcomes: A*

User's Guide: 2nd Edition. (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under Contract No. HHS290200500351 TO1.)

3. Neumann PJ, **Sanders GD**, Russell LB, Siegel JE, Ganiats TG. *Introduction*. Cost-Effectiveness in Health and Medicine. 2nd ed. New York, NY: Oxford University Press; 2016.
4. Neumann PJ, **Sanders GD**, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. *Overview of the Book*. Cost-Effectiveness in Health and Medicine. 2nd ed. New York, NY: Oxford University Press; 2016.
5. Neumann PJ, **Sanders GD**, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. *Recommendations on Perspectives of the Reference Case*. Cost-Effectiveness in Health and Medicine. 2nd ed. New York, NY: Oxford University Press; 2016.
6. Kuntz KM, Russell LB, Owens DK, **Sanders GD**. *Decision Models in Cost Effectiveness Analysis*. Cost-Effectiveness in Health and Medicine. 2nd ed. New York, NY: Oxford University Press; 2016.
7. Salomon JA, Trikalinos TA, **Sanders GD**, Mandelblatt JS. *Identifying and Quantifying the Consequences of Interventions*. Cost-Effectiveness in Health and Medicine. 2nd ed. New York, NY: Oxford University Press; 2016.
8. Trikalinos TA, Russell LB, **Sanders GD**. *Evidence Synthesis for Informing Cost Effectiveness Analysis*. Cost-Effectiveness in Health and Medicine. 2nd ed. New York, NY: Oxford University Press; 2016.
9. Prosser LA, Neumann PJ, **Sanders GD**, Siegel JE. *Reporting Cost Effectiveness Analyses*. Cost-Effectiveness in Health and Medicine. 2nd ed. New York, NY: Oxford University Press; 2016.
10. Neumann PJ, **Sanders GD**, Russell LB, Siegel JE, Ganiats TG, eds. Cost-Effectiveness in Health and Medicine. 2nd ed. New York, NY: Oxford University Press; 2016.

Abstracts

1. Owens DK, **Sanders GD**, Harris RA, McDonald KM, Hlatky MA. Cost-effectiveness of third-generation implantable cardioverter-defibrillators for prevention of sudden cardiac death. *Medical Decision Making* 1995;14:420.
2. Owens DK, **Sanders GD**, Heidenreich PA, McDonald KM, Dembitzer AD, Hlatky MA. Identification of patients at high risk for sudden cardiac death. *Medical Decision Making* 1996; 16:456.
3. Dembitzer A, **Sanders GD**, Owens DK. Medical management of BRCA-1 mutation carriers: A decision analysis of breast cancer detection and prevention strategies. *Medical Decision Making* 1996; 16:456.
4. Gould M, Dembitzer A, **Sanders G**, Large A, Milius MS, Garber A. Low molecular weight heparin for the treatment of acute deep vein thrombosis: A cost-effectiveness analysis; *JGIM* 1996; vol 11 suppl 1 p 58.
5. **Sanders GD**, Every NR, McDonald KM, Parsons LS, Heidenreich PA, Hlatky MA, Owens DK. Cost effectiveness of implantable cardiac defibrillators (ICDs) after myocardial infarction (MI). *Medical Decision Making* 1997; 17(4): 531.
6. **Sanders GD**, Hagerty CG, Sonnenberg FA, Hlatky MA, Owens DK. Distributed dynamic decision support using a web-based interface for prevention of sudden cardiac death. *Medical Decision Making* 1997; 17(4): 524.
7. Salpeter SR, **Sanders GD**, Salpeter EE, Owens DK. Cost effectiveness of monitored isoniazid prophylaxis for low risk tuberculin reactors over age 35. *Medical Decision Making* 1997; 17(4): 521.

8. Dembitzer AD, **Sanders GD**, Owens DK. Cost effectiveness of screening of breast cancer with BRCA1/BRCA2. *Medical Decision Making* 1997; 17(4): 531.
9. **Sanders GD**, Nease RF, Owens, DK. Development and pilot evaluation of automated computer-based creation of site-specific clinical-practice guidelines from decision models. *Medical Decision Making* 1998; 18(4): 462.
10. **Sanders GD**, Nease RF, Owens, DK. Design and implementation of a computer-based system to annotate decision models for use in guideline development. *Medical Decision Making* 1998; 18(4): 469.
11. Cheng CHF, **Sanders GD**, Heidenreich PA, McDonald KM, Lee BK, Larson MS, Hlatky MA, Owens DK. Cost effectiveness of radiofrequency ablation for treatment of paroxysmal supraventricular tachycardias. *Medical Decision Making* 1998; 18(4): 458.
12. **Sanders GD**, Every NR, McDonald KM, Parson LS, Heidenreich PA, Hlatky MA, Owens, DK. Cost effectiveness of implantable cardioverter defibrillators and amiodarone after myocardial infarction. *Journal of the American College of Cardiology* 1999; 33(2): Supplement A: 307A.
13. **Sanders GD**, Hlatky MA, Heidenreich PA, McDonald KM, Owens DK. Use of decision models to extrapolate results from clinical trials: Cost effectiveness of the implantable cardioverter defibrillator (ICD). *Medical Decision Making* 1999; 19(4): 519
14. Haug CJ, **Sanders GD**, Luu V, Cody SH, Barnato AE, Owens DK. Cost effectiveness of screening women for *chlamydia trachoma*. *Medical Decision Making* 1999; 19(4): 539
15. Dembitzer AD, **Sanders GD**, Goldstein MK, Owens DK. Cost effectiveness of programs that screen for BRCA mutations in women. *Medical Decision Making* 1999; 19(4): 526
16. Heidenreich PA, **Sanders GD**, Hlatky MA, McDonald KM, Owens DK. Cost effectiveness of screening survivors of myocardial infarction for prophylactic defibrillator implantation. *Medical Decision Making* 1999; 19(4): 519
17. Alloggiamento T, Khalessi A, Lin O, **Sanders GD**, Hlatky MA, Owens DK. Cost effectiveness of intracoronary brachytherapy for prevention of restenosis in single-vessel coronary artery disease. *Medical Decision Making* 1999; 19(4): 539
18. Heidenreich PA, **Sanders GD**, Hlatky MA, McDonald KM, Owens DK. Should survivors of myocardial infarction be screened for risk of sudden death? A cost-effectiveness analysis. *Journal of the American College of Cardiology* 2000. 35(2): Supplement A: 550.
19. Alloggiamento T, **Sanders GD**, Khalessi A, Lin OS, Hlatky MA, Yeung AC, Owens DK. Cost-effectiveness of emerging antiproliferative therapies that reduce restenosis after coronary angioplasty. *Journal of the American College of Cardiology* 2000. 35(2): Supplement A: 550.
20. **Sanders GD**, Nease RF, Hlatky MA, Owens DK. Development of interactive web-based guidelines for prevention of sudden cardiac death. *PACE* April 2000, 23(4 part II), 749.
21. Barnato AE, **Sanders GD**, Owens DK. Cost-effectiveness of a potential vaccine for *Coccidioides immitis*. Third Annual Conference on Vaccine Research, sponsored by the National Foundation for Infectious Diseases, Washington, D.C., April 30-May 2, 2000.
22. **Sanders GD**, Nease RF, Owens DK. Publishing web-based guidelines using interactive decision models [poster] JAMIA 2000.
23. Heidenreich PA, **Sanders GD**, Hlatky MA, Buxton AE, Hafley GE, Lee KL, McDonald KM, Owens DK. Cost-effectiveness of screening patients with low ejection fraction for prophylactic defibrillator implantation. *Medical*

Decision Making 2000 20(4); 484.

24. Barnato AE, **Sanders GD**, Owens DK. A Markov model to assess the cost-effectiveness of *C. immitis* vaccination. *Medical Decision Making* 2000 20(4); 487
25. Lin OS, Keefe, EB, **Sanders GD**, Owens DK. Cost-effectiveness of screening strategies for hepatocellular carcinoma in cirrhotic patients *Medical Decision Making* 2000 20(4); 477.
26. Owens DK, **Sanders GD**, Sundaram V, Lazzeroni LC, Yano EM, Tempio P, Phillips B, McWhorter V, Douglass L, Bozzette SA. Policies for Human Immunodeficiency Virus screening in Department of Veterans Affairs hospitals. *Journal of General Internal Medicine* 2001; 16 (Supplement 1): 211.
27. Auerbach AD, **Sanders GD**, Hambleton J. Cost effectiveness of screening for hypercoagulable states in patients with deep venous thrombosis. *Journal of General Internal Medicine* 2001:16 (suppl 1).
28. Groeneveld PW, Kwong JL, Liu Y, Rodriguez AJ, Jones MP, **Sanders GD**, Garber AM. The cost-effectiveness of automated external defibrillators on commercial aircraft (Abstract). *Journal of General Internal Medicine* 2001:16(suppl 1):137.
29. **Sanders GD**, Parmar PK. Use of decision models in clinical-practice guideline development *Academy for Health Services Research and Health Policy* 2001
30. Groeneveld PW, Kwong JL, Liu Y, Rodriguez AJ, Jones MP, **Sanders GD**, Garber AM. The cost-effectiveness of automated external defibrillators on commercial aircraft. *Academy for Health Services Research and Health Policy* 2001
31. Gould MK, **Sanders GD**, Barnett PG, MacLean CC, Rydzak CE, McClellan MB, Owens DK. Cost effectiveness of alternative management strategies for patients with solitary pulmonary nodules. *Medical Decision Making* 2001 21(6). 528
32. **Sanders GD**, Taira AV. Cost effectiveness of a potential human papillomavirus vaccine. *Medical Decision Making* 2001 21(6). 529
33. **Sanders GD**, Bilir SP, Lin DS, Rydzak CE, Owens DK, Gould MK. Automated customization of recommended strategies for management of solitary pulmonary nodules. *Medical Decision Making* 2002; 22(6): 535.
34. **Sanders GD**, Bilir SP, Lin DS, Rydzak CE, Douglass L, Sundaram V, Owens DK. Automated and evidence-based site-specific guidelines for HIV screening. *Medical Decision Making* 2002; 22(6): 549.
35. **Sanders GD**, Owens DK, Bilir SP, Sinaiko A, Valk P, Maisey M. Cost effectiveness of Positron Emission Tomography (PET) before hepatic resection for colorectal metastases. *Medical Decision Making* 2002; 22(6): 543.
36. Sundaram V, Douglass L, Lazzeroni LC, **Sanders GD**, Tempio P, Bergen MR, Owens DK.. A randomized trial of an intervention to improve HIV screening. *Medical Decision Making* 2002; 22(6): 542
37. Bilir SP, Rydzak CE, Sinaiko AE, **Sanders GD**. Cost effectiveness of vaccinating college freshmen against meningitis. *Medical Decision Making* 2002; 22(6): 544.
38. Silverman J, Bundorf MK, Rydzak CE, Dembitzer AD, Enthoven A, Owens DK, **Sanders GD**. Cost effectiveness of assessing patient preferences for treatment of breast and ovarian cancer susceptibility. *Medical Decision Making* 2002; 22(6): 554.

39. Fowler R, Nouri B, **Sanders GD**, Gastwirth J, Peterson D, Broker A, Bravata D, Owens DK. Cost-effectiveness of the human anthrax vaccine and antimicrobial therapy for urban populations at risk for bioterror attacks. *Medical Decision Making* 2002; 22(6): 554.
40. **Sanders GD**, Bayoumi A, Sundaram V, Bilir SP, Rydzak CE, Douglass L, Holodniy M, Owens DK. Cost effectiveness of HIV screening in acute care settings in the era of highly active antiretroviral therapy. *Medical Decision Making* 2002; 22(6): 562.
41. Owens DK, Sundaram V, Lazzeroni LC, Douglass L, Tempio P, **Sanders GD**, Holodniy M. HIV testing appropriateness and predictors of HIV infection in Department of Veterans Affairs Health Care Systems. *Medical Decision Making* 2002; 22(6): 534
42. Fowler R, Hill-Popper M, Petrou C, Stasinou J, **Sanders GD**, Garber AM. Cost-effectiveness of recombinant human activated protein C in the treatment of patients with severe sepsis. *Medical Decision Making* 2002; 22(6): 533
43. Taira AV, **Sanders GD**. Evaluation of potential human papillomavirus vaccine rollout strategies using a dynamic transmission model. *Medical Decision Making* 2002; 22(6): 535.
44. Scott GC, Shachter R, **Sanders GD**, Lenert L. Design and pilot evaluation of an automated individualized patient decision support framework. *Medical Decision Making* 2002; 22(6): 553.
45. Vij R, Triadafilopoulos G, Owens DK, Kunz P, **Sanders GD**. Cost effectiveness analysis of treatments for dysplasia in Barrett's esophagus. *Gastrointestinal Endoscopy* 2003, 57(5): AB79
46. Munakata M, Woolcott J, Anis A, Sculpher M, Yu W, **Sanders GD**, Bayoumi A, Gulbinas V, Philips Z, Owens DK, and the OPTIMA Team. Design of a prospective economic evaluation for a tri-national clinical trial in HIV patients (OPTIMA). 3rd Joint Meeting of the International Society for Clinical Biostatistics and the Society for Clinical Trials. *Controlled Clinical Trials* 2003; 24: 173S.
47. **Sanders GD**, Bayoumi AM, Sundaram V, Neukermans CP, Holodniy M, Owens DK. Effect of transmission on the cost effectiveness of screening for HIV. *Medical Decision Making* 2003, 23(6): 585.
48. **Sanders GD**, Nouri B, Choudhry K, Owens DK, Hlatky MA. Potential cost effectiveness of genetic screening for sudden cardiac death. *Medical Decision Making* 2003, 23(6): 579.
49. Munakata J, **Sanders GD**, Owens DK, Bayoumi AM. Cost effectiveness of enfuvirtide in the treatment of drug resistant HIV infection. *Medical Decision Making* 2003, 23(6): 569.
50. Widman AJ, **Sanders GD**, Stockdale FE, Plevritis SK. The cost-effectiveness of dose-dense versus conventionally scheduled combination chemotherapy as postoperative adjuvant treatment for node-positive primary breast cancer. *Medical Decision Making* 2003, 23(6): 576.
51. Perlroth DJ, **Sanders GD**, Gould MK. Cost-effectiveness of thrombolytic therapy with alteplase in patients with submassive pulmonary embolism and right ventricular dysfunction. *Medical Decision Making* 2003, 23(6): 569.
52. Vij R, Triadafilopoulos G, Owens DK, Kunz P, **Sanders GD**. Cost effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. *Medical Decision Making* 2003, 23(6): 585.
53. Hersh AL, **Sanders GD**. HIV testing: what can we learn and apply from the threshold model? *Medical Decision Making* 2003, 23(6): 549.
54. Owens DK, Sundaram V, Douglass L, Lazzeroni L, Holodniy M, Margolis D, **Sanders GD**, Taylor K, VonGroningen R, Shadle VM, Gyuricza D, McWhorter VC, Agoncillo T, Paulk P, Haren N, Tuen M, Dwyer

- A, Nyland J, Tempio T, Khayr W, Dietzen D, Jensen P, Simberkoff M, Bozzette SA. Seroprevalence of HIV infection at VA health care systems. *Medical Decision Making* 2003, 23(6): 569.
55. Taira AV, Neukermans CP, **Sanders GD**. Modeling subpopulation dynamics in vaccine cost-effectiveness studies. *Medical Decision Making* 2003, 23(6): 562.
 56. Perlroth DJ, **Sanders GD**, Gould MK. Cost-Effectiveness of Thrombolytic Therapy with Alteplase for Patients with Acute Pulmonary Embolism (PE) and Systemic Arterial Hypotension. *American Journal of Respiratory and Critical Care Medicine* 2005
 57. Perlroth DJ, **Sanders GD**, Gould MK. Cost-Effectiveness of Thrombolytic Therapy with Alteplase Based on a Randomized Controlled Trial (RCT) in Patients with Submassive Pulmonary Embolism (PE) and Right Ventricular Dysfunction (RVD). *American Journal of Respiratory and Critical Care Medicine* 2005
 58. Joyce V, Araki SS, Sundaram V, Hill AK, Baker F, Munakata J, Kyriakides TC, **Sanders GD**, Griffin SC, Holodniy M, Brown S, Sculpher M, Anis AH, Yu W, Owens DK, and the OPTIMA Investigators. Utility-based assessments of quality of life in a randomized trial of antiretroviral therapy in advanced HIV disease. *Medical Decision Making* 2005, 25(1): E8.
 59. Araki SS, Guh DP, Singer J, Joyce V, Sundaram V, Munakata J, Hill AK, Sun H, Griffin SC, **Sanders GD**, Bayoumi AM, Holodniy M, Brown S, Sculpher M, Yu W, Owens DK, and the OPTIMA Investigators. The impact of AIDS-related events and non-AIDS serious adverse events on health-related quality of life in a multinational trial of antiretroviral therapy. *Medical Decision Making* 2005, 25(1): E52.
 60. **Sanders GD**, Hlatky MA, Owens DK. Cost effectiveness of the implantable cardioverter defibrillator in the MADIT-II population. *Medical Decision Making* 2005, 25(1): E38.
 61. Krahn M, Witkos M, **Sanders GD**, Sugano D, Cantor SB. What would make the Society and the Annual Meeting better? A survey of the Society for Medical Decision Making membership. *Medical Decision Making* 2005, 25(1): E53.
 62. Bayoumi AM, **Sanders GD**, Munakata J, Owens DK. Potential cost effectiveness of aggressively treating multi-drug-experienced HIV-positive patients. *Medical Decision Making* 2005, 25(1): E35.
 63. **Sanders GD**, Sundaram V, Bayoumi AM, Holodniy M, Owens DK. Cost effectiveness of HIV screening in the elderly. *Medical Decision Making* 2005, 25(1): E15.
 64. **Sanders GD**, Lin DS, Chan JK, Gould MK. ALCHEMIST-FRONTIER: a web-based application to facilitate analysis of decision models comparing multiple possible sequences of diagnostic tests. *Medical Decision Making* 2005, 25(1): E51.
 65. **Sanders GD**, Bayoumi AM, Sundaram V, Lazzeroni L, Holodniy M, Owens DK. Cost effectiveness of screening for HIV. Abstract Book, 2005 National HIV Prevention Conference, June 12-15, 2005, Atlanta, Georgia, p. 24-25.
 66. Owens DK, **Sanders G**, Bayoumi A, Holodniy M. Cost effectiveness of screening for HIV in the United States in the era of highly active antiretroviral therapy. *Russian Journal of AIDS, Cancer and Public Health* 2005; 9(2):120.
 67. Dembitzer, AD, **Sanders GD**, Carter EH, Owens DK. Evaluation of the effectiveness and cost-effectiveness of proband testing for BRCA1/2 mutations. *Medical Decision Making* 2006; 26(1): E28
 68. Hagerty CG, **Sanders GD**, Sonnenberg FA. Elephant nodes save the day: More efficient cost effectiveness evaluation of strategies involving embedded decisions. *Medical Decision Making* 2006; 26(1): E54

69. Tole SP, **Sanders GD**, Bayoumi AM, Galvin CM, Vinichenko TN, Long EF, Brandeau ML, Owens DK. The cost effectiveness of HIV screening in a resource limited country: a model of screening in Russia. *Medical Decision Making* 2006; 26(1): E6
70. Long EF, Brandeau ML, Galvin CM, Vinichenko TN, Tole SP, Schwartz A, **Sanders GD**, Owens DK. Treating injection drug users with antiretroviral therapy: Effect on the HIV epidemic in Russia. *Medical Decision Making* 2006; 26(1): E7
71. Long EF, Brandeau ML, Galvin CM, Vinichenko TN, Tole SP, Schwartz A, **Sanders GD**, Owens DK. The cost effectiveness of antiretroviral therapy for injection drug users in Russia. *Medical Decision Making* 2006; 26(1): E3.
72. **Sanders GD**, Provenzale D, Lee AJ, Niedziecki D, Rockey D. Imaging tests and surveillance strategies for colorectal cancer: Is computed tomographic colonography a cost-effective option? *Medical Decision Making* 2006; 26(1): E4
73. **Sanders GD**, Dembitzer AD, Carter EH, Goldstein MK, Bravata DM, Owens DK. Preference-based decision making to guide testing for breast cancer genes. *Medical Decision Making* 2006; 26(1): E10
74. **Sanders GD**, Hlatky MA, Owens DK. Inappropriate Shocks Reduce Implantable Cardioverter Defibrillator Cost Effectiveness (AB4-2). *Heart Rhythm Journal*. 2006; 3 (5) Supplement S: S7.
75. Vijayaraghavan A, Efrusy M, Mazonson P, Ebrahim O, Sanne I, Santas C, **Sanders G**. Cost Effectiveness of Initiating and Monitoring HAART Based on WHO Versus US DHHS Guidelines in the Developing World. *AIDS 2006 – XVI International AIDS Conference*. 2006 TUAD0201.
76. **Sanders GD**, Ferko N, Standaert B, Kruzikas D, Taylor DCA, Juday T. Modeling the Long-Term Clinical Impact of HPV Vaccination in the US: The Impact of Herd Immunity on Cervical Cancer and Pre-Cancerous Lesions. 23rd International Papillomavirus Conference.
77. **Sanders GD**, Bayoumi AM, Owens DK. Cost Effectiveness of Screening with Streamlined Counseling. *Medical Decision Making* 2006
78. Dosiou C, **Sanders GD**, Araki SS, Crapo LM, Screening Pregnant Women for Autoimmune Thyroid Disease is Cost-Effective. *Medical Decision Making* 2006
79. **Sanders GD**, Kulasingam SL, Havrilesky LJ, Myers ER. Can Screening ever be a Feasible Method for Ovarian Cancer Mortality Reduction? *Medical Decision Making* 2006
80. Thompson EM, **Sanders GD**, Trotter PR, Patz EF, Owens DK, Gould MK. Validation of two models to estimate the pre-test probability of malignancy in patients with solitary pulmonary nodules. *American Journal of Respiratory and Critical Care Medicine* 2007;175:A870.
81. Thompson EM, **Sanders GD**, Trotter PR, Patz EF, Owens DK, Gould MK. Validation of a decision model for managing solitary pulmonary nodules. *American Journal of Respiratory and Critical Care Medicine* 2007;175:A869.
82. Cox CE, Carson SS, Govert JA, Chelluri L, **Sanders GD**. An Economic Evaluation of Prolonged Mechanical Ventilation, *American Journal of Respiratory and Critical Care Medicine* 2007;175: A779
83. **Sanders GD**, Anaya H, Asch S, Goetz M, Hoang T, Golden J, Gifford A, Bowman C, Owens DK. Cost Effectiveness of Rapid HIV Testing with Streamlined Counseling. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention.
84. **GD Sanders**, DCA Taylor, A Pandya, R Iskandar, DT Kruzikas. Modeling the Impact of Vaccination against Cervical Cancer until Steady State: Cost-Effectiveness and Reduction in Outcomes” *Health Technology Assessment International*

85. Long EF, Brandeau ML, Galvin CM, Vinichenko TN, Tole SP, **Sanders GD**, Owens DK. Evaluating the cost effectiveness of expanding antiretroviral therapy (ARV) in Russia and the effect of reduced ARV Price. Proceedings of the 16th International Conference on AIDS, Cancer and Public Health, St Petersburg, Russia, May 28-June 1, 2007. Russian Journal of AIDS, Cancer, and Public Health 2007; 11: 119.
86. Tole SP, **Sanders GD**, Bayoumi AM, Galvin CM, Vinichenko TN, Brandeau ML, Owens DK. The cost effectiveness of HIV screening in Russia. Proceedings of the 16th International Conference on AIDS, Cancer and Public Health, St Petersburg, Russia, May 28-June 1, 2007. Russian Journal of AIDS, Cancer, and Public Health 2007; 11: 129
87. **Sanders GD**, Schmidler SC. Effect of HPV Vaccine Characteristics and Implementation Strategies on Incidence of Disease. Medical Decision Making 2008; 28 (1): E14.
88. **Sanders GD**, Galhenage SP, Patel K, Schulman KA, McHutchison JG. Modeling the Potential Cost-Effectiveness of Adding a Novel STAT-C Agent to Current Standard Therapy in Patients With Genotype 1 Chronic Hepatitis C Infection. Medical Decision Making 2008; 28(1): E34
89. **Sanders GD**, Anaya H, Asch S, Goetz M, Hoang T, Golden J, Gifford A, Bowman C, Owens DK. Cost Effectiveness of Strategies to Improve HIV Testing and Receipt of Results. Medical Decision Making 2008; 28(1): E21.
90. Bendavid E, Bayoumi AM, Katzenstein DA, **Sanders GD**, Owens DK. Cost effectiveness of HIV monitoring strategies in resource-limited settings. Medical Decision Making 2008; 28(1): E42.
91. Al-Khatib SM, Wang Y, Lee KL, Mark DB, **Sanders GD**, Peterson E, Curtis J, Bardy GH. Do Patients Who Meet SCD-HeFT Criteria in Clinical Practice Differ from Patients Enrolled in SCD-HeFT? American Heart Association 2007
92. Al-Khatib SM, Wang Y, Zareba W, Peterson E, **Sanders GD**, Krumholz H, Lee KL, Mark D, Moss AJ. Patients Who Receive an Implantable Cardioverter Defibrillator for MADIT-II Criteria in Clinical Practice are Different from Patients Enrolled in MADIT-II. American Heart Association 2007
93. Galhenage SP, **Sanders GD**, Patel K, Schulman KA, McHutchison JG. Modeling the potential cost-effectiveness of adding a novel STAT-C agent to current standard therapy in patients with genotype 1 chronic hepatitis C infection. American Association for the Study of Liver Diseases 2007
94. **Sanders GD**, Kruzikas DT, Taylor DC. Modeling the effect of prophylactic cervical cancer vaccination catch-up programs on prevalence of HPV infection in the United States. 24th International Papillomavirus Conference Proceedings 2007
95. Huh WK, Herzog TJ, Taylor DC, Weinstein MC, Kruzikas DT, **Sanders GD**. Why we should consider vaccination against cervical cancer for older females: Estimating the impact based on an HPV transmission and natural history model in the United States. Gynecologic Oncology. March 2008; 108(3) Supplement 1: S93.
96. Havrilesky LJ, Kulasingam S, **Sanders GD**, Myers ER. Can screening for ovarian cancer achieve mortality reduction and be cost effective? Gynecologic Oncology. March 2008; 108(3) Supplement 1: S114.
97. Huh W, Herzog T, Taylor D, Kruzikas D, Pawar V, Gilmore K, Naik S, Thompson D, Weinstein M, **Sanders GD**. Estimating the impact of a cervical cancer vaccination Pre- and Post- exposure to human papillomavirus: reductions in cervical disease based on a mathematical model. Interscience Conference on Antimicrobial Agents and Chemotherapy
98. **Sanders GD**, MH Kong, SM Al-Khatib, ED Peterson. Cost effectiveness of the implantable cardioverter defibrillator in the elderly. American Heart Association 2008

99. Bendavid E, **Sanders GD**, Owens DK. Cost effectiveness of expanded testing for HIV in highly endemic regions. *Medical Decision Making* 2008
100. Al-Khatib SM, Piccini JP, Knight D, Stewart M, Clapp-Channing N, **Sanders GD**. Remote Monitoring of Implantable Cardioverter Defibrillators versus Quarterly Device Interrogations in Clinic: Results from a Randomized Clinical Trial. *Heart Rhythm Society* 2009
101. **Sanders GD**, Inoue L, Samsa GP, Gray R, Matchar DB. Bayesian Methods in RCTs: ICD Therapy for Prevention of Sudden Cardiac Death. *Medical Decision Making* 2009
102. Al-Khatib SM, Hellkamp A, Curtis J, Peterson E, **Sanders GD**, Mark D, Heidenreich P, Hernandez A, Curtis L, Hammill S. Prevalence of Non-evidence-based ICD implantations in the United States: Results from the NCDR-ICD Registry/ *Heart Rhythm Society* 2010
103. Al-Khatib SM, **Sanders GD**, Matlock DD, O'Brien S, Zimme Lr, Masoudi FA, Peterson ED. Are Physicians Less Likely to Offer an Implantable Cardioverter Defibrillator to Women, Racial Minorities, and Older Patients?. *American College of Cardiology* 2010
104. Allen LaPointe NM, Al-Khatib SM, Piccini JP, Atwater BD, Honeycutt E, Thomas K, Shah B, **Sanders GD**, Peterson ED. Guideline Based Use of Implantable Cardioverter Defibrillators in Patients with Left Ventricular Systolic Dysfunction in Clinical Practice. *AHA Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference* 2010
105. Matlock DD, Kutner JS, Emsermann C, Al-Khatib SM, **Sanders GD**, Rumsfeld J, Dickinson M, Masoudi FA.. Regional Variations in Physicians' Attitudes Towards Implantable Cardioverter-Defibrillators: A Report from the NCDR ICD Registry. *AHA Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference* 2010
106. Matlock DD, Masoudi FA , Emsermann C, Al-Khatib SM, **Sanders GD**, Rumsfeld J, Dickinson M, Kutner JS. What is More Important in Cardiologists' Decision Making Around Implantable-Cardioverter Defibrillators (ICD), Mortality Data or Patient Preferences?: A Report from the NCDR ICD Registry. *AHA Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference* 2010
107. Al-Khatib SM, Hellkamp A, Peterson E, **Sanders GD**, Mark D, Hernandez A, Curtis L, Hammill S. Prevalence of Non-evidence-based ICD implantations in the United States: Results from the NCDR-ICD Registry. *Heart Rhythm Society* 2010
108. Bayoumi AM, Joyce VR, Barnett PG, Griffin S, Sun H, **Sanders GD**, Bansback NJ, Holodniy M, Brown ST, Kyriakides TC, Sculpher M, Anis AH, Owens DK. Cost-Effectiveness of Novel Antiretrovirals for Human Immunodeficiency Virus Infection. *Medical Decision Making* 2010.
109. Hess PL, Laird A, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Hall WJ, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Al-Khatib SM, Piccini JP, Inoue LY, **Sanders GD**. Mortality Benefit of Primary Prevention Implantable Cardioverter-Defibrillators as a Function of Time After Myocardial Infarction: A Meta-Analysis Using Patient-Level Data on 3,038 Patients Enrolled in 5 Clinical Trials. *Heart Rhythm* 2012.
110. Gould MK, Simkovich S, Mestaz PJ, Daniel J, **Sanders GD**, Silvestri G. Predicting the Probability of Malignancy in Patients with Pulmonary Nodules: Comparison of Clinical Judgment with two Validated Models. *American Thoracic Society International Conference* 2012.
111. Myers ER, Havrilesky LJ, Gierisch J, Moorman PG, Dinan MA, Coeytaux RR, Urrutia RP, Lowery WJ, Hasselblad V, McBroom AJ, **Sanders GD**. Net Effect of Current Patterns of Oral Contraceptive Use on Potentially Fatal Outcomes in the United States. *Medical Decision Making* 2012.
112. Myers ER, Havrilesky LJ, Gierisch J, Moorman PG, Dinan MA, Coeytaux RR, Urrutia RP, Lowery WJ, Hasselblad V, McBroom AJ, **Sanders GD**. Using Net Benefits and Acceptability Curves to Quantify

Uncertainty About Tradeoffs Between Harms and Benefits of Oral Contraceptives. *Medical Decision Making* 2012.

113. Allen LaPointe NM, Lokhnygina Y, **Sanders GD**, Peterson E, Al-Khatib S. Is Selection of Antiarrhythmic Drugs for Atrial Fibrillation Consistent with Guideline Recommendations: Results from a Large Contemporary Community Cohort. *American Heart Association* 2012.
114. Pun PH, AlKhatib SM, Edwards R, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman RC, Dorian P, Hallstrom AP, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LYT, **Sanders GD**. Influence of Chronic Kidney Disease on the Efficacy of Primary Prevention Implantable Cardioverter Defibrillators: A Meta-Analysis of Three Randomized Trials. *American College of Cardiology* 2013.
115. Steinberg BA, AlKhatib SM, Edwards R, Han JY, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman RC, Dorian P, Hallstrom AP, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LYT, **Sanders GD**. Implantable Cardiac Defibrillator Therapy in Patients with Comorbidities: Results from a Combined Analysis of Five Randomized Clinical Trials. *Heart Rhythm Society* 2013
116. Sanders GD, Inoue LYT, Edwards R, Al-Khatib SM, Han JY, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB. Harnessing the Power of Bayesian Statistics and Patient-Level Data to Predict the Effectiveness of Implantable Cardioverter Defibrillator (ICD) Therapy in Patient Subgroups. *Society for Medical Decision Making Annual Meeting* 2013.
117. **Sanders GD**, Neumann PJ, Russell L, Siegel J, Ganiats T. 2nd Panel on Cost Effectiveness in Health and Medicine. *Society for Medical Decision Making Annual Meeting* 2014.
118. Zeitler EP, Patel D, Hasselblad V, **Sanders GD**, Al-Khatib SM. Complications from replacement of cardiac implantable electronic device generators in response to FDA recall: a systematic review and meta-analysis. *Heart Rhythm Society* 2015
119. Zeitler EP, Hellkamp AS, Schulte P, Fonarow GC, Hernandez AF, Peterson ED, **Sanders GD**, Yancy CW, Al-Khatib SM. Primary Prevention Implantable Cardioverter Defibrillators are Associated with Improved Survival in Women. *Heart Rhythm Society* 2015
120. Coeytaux R, Befus D, Hull S, Strand de Oliveira J, **Sanders GD**, Weinberger M. Assessment of a Personalized Health Care Intervention for Chronic Daily Headache. *Agency for Healthcare Research and Research Annual Meeting* 2015
121. Friedman DJ, Al-Khatib SM, Zeitler EP, Han JY, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LY, **Sanders GD**. New York Heart Association Class and the Mortality Benefit From Primary Prevention Implantable Cardioverter Defibrillator Use: A Pooled Analysis of 4 Randomized Control Trials. *Circulation*. 2016;134:A12202
122. **Sanders GD**, Basu A, Myers E, Meltzer D. Potential Value of an Aspirin-Dose Trial for Secondary Prevention of Coronary Artery Disease: Informing PCORI and Future Trial Design. *Circulation*. 2016;134:A20405
123. Zeitler EP, Al-Khatib SM, Friedman DJ, Han JY, Bardy GH, Bigger JT, Buxton AE, Moss AJ, Lee KL, Steinman R, Dorian P, Hallstrom A, Cappato R, Kadish AH, Kudenchuk PJ, Mark DB, Inoue LY, **Sanders GD**. Predicting Appropriate Shocks In Patients With Heart Failure: Patient Level Meta-analysis From SCD-HeFT and Madit II. *Circulation*. 2016;134:A11595

Letters and Commentaries

1. Salpeter SR, **Sanders GD**, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors [Letter]. *Annals of Internal Medicine* 1998; 128.
2. Salpeter SR, **Sanders GD**. Prophylaxis with isoniazid for low risk tuberculin reactors. *Cardiology Review* 1998; 15:398-406.
3. Heidenreich PA, Cheng CHF, **Sanders GD**, Hlatky MA, McDonald KM, Lee BK, Larson MS, Owens DK. Radiofrequency ablation for supraventricular tachycardias. *Cardiology Review* 2001;18(11):8-13.
4. **Sanders GD**, Bayoumi AM, Owens DK. Cost effectiveness of screening for HIV (correspondence). *New England Journal of Medicine* 2005; 352:2137-2139.
5. Hlatky MA, **Sanders GD**. Commentary: Multislice computed tomography detected coronary artery disease. *Evidence Based Medicine* 2006; 11: 24.
6. **Sanders GD**, Hlatky MA, Owens DK. Cost effectiveness of ICDs (correspondence). *New England Journal of Medicine* 2006; 354:205-207.
7. Helfand M, **Sanders GD**. Policy rounds: a new series and a call for papers. *Med Decis Making*. 2008;28(2):169-71.
8. **Sanders GD**. Modeling bioterrorism and disaster preparedness: SMDM's recommendations for design and reporting. *Med Decis Making*. 2009 Jul-Aug;29(4):412-3
9. Hess PL, Al-Khatib SM, Inoue LY, **Sanders GD**. When to implant an ICD following a myocardial infarction? *Heart Rhythm*. 2013 Sep;10(9):e79. doi: 10.1016/j.hrthm.2013.07.035. Epub 2013 Jul 24. PubMed PMID: 23891957; PubMed Central PMCID: PMC4269553.
10. Zeitler EP, Hellkamp AS, Schulte PJ, Fonarow GC, Hernandez AF, Peterson ED, **Sanders GD**, Yancy CW, Al-Khatib SM. Response to Letter Regarding Article, "Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women". *Circ Heart Fail*. 2016 May;9(5). pii: e003135. doi: 10.1161/CIRCHEARTFAILURE.116.003135. PubMed PMID: 27162231; PubMed Central PMCID: PMC4869988.
11. Myers ER, Moorman P, **Sanders GD**. Breast Cancer Screening: Benefit or Harm?--Reply. *JAMA*. 2016 Apr 5;315(13):1402-3. doi: 10.1001/jama.2015.19129. PubMed PMID: 27046371.
12. **Sanders GD**, Neumann PJ, Russell LB. Updated Recommendations for Cost-effectiveness Studies-Reply. *JAMA*. 2017 Jan 3;317(1):90. doi: 10.1001/jama.2016.17839. PubMed PMID: 28030697.

Consultant appointments:

2016	Consultant for Centers for Disease Control and Prevention (Atlanta, GA). Short course on Cochrane Systematic Review Methods for CDC Guideline Development.
2014 – 2016	Consultant for Angel Medical Systems (Shrewsbury, NJ) Potential cost effectiveness of intracardiac ischemia monitoring
2014 – 2016	Consultant for Zoll Medical Corporation (Chelmsford, MA) Potential cost effectiveness of the wearable cardioverter defibrillator in patients in the early post myocardial infarction period
2007 – 2010	Consultant for GE Healthcare (Princeton, NJ). Economic model of selection of patients for ICD implantation

2006 – 2011	Consultant for GlaxoSmithKline (Philadelphia, PA) Transmission dynamics of Human Papillomavirus vaccination
2005 – 2006	Consultant for Mosaic Health Care Consultants (Larkspur, CA). Cost effectiveness analysis of HIV treatment guidelines in South Africa
2005	Consultant for Pointe Biomedical Corporation (San Carlos, CA) Risk/benefit analysis of myocardial perfusion imagine
2003 – 2006, 2009	Consultant for Blue Cross Blue Shield Association Medical Advisory Panel (Chicago, IL) Cost effectiveness of implantable cardioverter defibrillator in primary prevention of sudden cardiac death, cost effectiveness of computed tomographic angiography in diagnosis of coronary artery disease
1997 – 1998	Consultant for Technology Assessment Group (San Francisco, CA). Literature review, data analysis, and decision modeling for diagnosis of patients who present to the ER with suspected myocardial infarction.
1996	Consultant for Shelley Salpeter M.D. (Santa Clara Valley Medical Center) providing risk-benefit and cost-effectiveness decision modeling for the use of Isoniazid prophylaxis for tuberculin reactors over age 35.
1995 – 1996	Consultant for Technology Assessment Group (San Francisco, CA and Montreal, Quebec). Performed data analysis, and decision modeling for a budgetary impact study.

Professional awards and special recognitions:

2001	Outstanding Paper by a Young Investigator, Society of Medical Decision Making (for: Sanders GD, Nease RF, Owens, DK. Design and pilot evaluation of a system to develop computer-based site-specific practice guidelines from decision models. <i>Medical Decision Making</i> 2000; 20:145-159)
1997	1 st Place, Fifteenth annual Lee Lusted National Student Research Competition, Nineteenth Annual Meeting, Society for Medical Decision Making
1989-1993	Princeton University Scholarship Unisys Canada Inc. National Merit Scholarship John B. Lynch Scholarship

Organizations and participation:

1997 – 2007	Medical Informatics Interest Group (Group Leader), Society for Medical Decision Making
1997 – present	Reviewer for <i>Medical Decision Making</i> , <i>American Journal of Medicine</i> , <i>BMJ</i> , <i>Lancet</i> , <i>Society of General Internal Medicine</i> , <i>JAMA</i> , <i>American Heart Journal</i> , <i>New England Journal of Medicine</i> , <i>Annals of Internal Medicine</i> , <i>JAIDS</i>
1999 – 2003	Admission Committee, Medical Information Sciences Training Program, Stanford University
1999 – 2002	Education Committee, Society for Medical Decision Making
1999 – 2008	Publications Committee, Society for Medical Decision Making
1999 – 2007	Web Editor, Society for Medical Decision Making
1999 – 2001	AHRQ Study Section member, Health Care Technology and Decision Sciences
2000 – 2002	Trustee, Society for Medical Decision Making
2000 – 2003	Editorial Board, <i>Medical Decision Making</i> Journal
2000 – 2003	Executive committee, Biomedical Informatics, Stanford University
2001	AHRQ Special Emphasis Panel member, Patient Safety

2001 – 2003 Doctoral dissertation qualifying examination committee, Biomedical Informatics, Stanford University

2001 Co-chair, Society for Medical Decision Making Task Force on Cost-Effectiveness Analysis Reporting Guidelines

2003 Annual Meeting Co-chair abstract selection committee (Decision and Economic Analysis), Society of General Internal Medicine

2004 Chair, scientific review committee, 26th Annual Meeting of the Society for Medical Decision Making

2004 – 2007 Faculty of 1000, Evidence based health care evaluation board

2004 Co-director, Think Tank Meeting: Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy in Patients With Left Ventricular Dysfunction

2004 Vice-President Elect, Society for Medical Decision Making

2005 Co-director, Think Tank Meeting: Cost Effectiveness of the ICD in Primary Prevention Trials

2005 Meeting co-chair, 27th Annual Meeting of the Society for Medical Decision Making

2005 – 2006 Vice President, Society for Medical Decision Making

2005 – 2006 Chair, Education Committee, Society for Medical Decision Making

2005 – present Editorial Board, *American Heart Journal*

2005 – 2006 University of Alberta/Capital Evidence-Based Practice Center, Efficacy and Effectiveness of CRT and ICD Technical Expert Panel

2005 Ad Hoc reviewer for the US Army Medical Research and Materiel Command

2006 Ad-Hoc reviewer for the UK Department of Health

2006 Chapter leader for AHRQ reference document “Registries for Evaluating Patient Outcomes”

2006 Co-director, Think Tank Meeting: Preventing Tomorrow’s Sudden Cardiac Death Today: Risk Stratification for Sudden Cardiac Death

2006 – 2008 National ICD Registry Workgroup, Member

2006 – 2007 Editorial Consultant, Physician’s Information and Education Resource (PIER), Sudden Cardiac Death module

2006 – present Core Member, Duke University Interdisciplinary Medical Decision Making Initiative

2006 – 2007 President Elect, Society for Medical Decision Making

2007 – 2008 NIA Study Section member, P01 grant review

2007 – 2008 AHRQ, Special Emphasis Panel Study Section member

2007 – 2010 AHRQ Study Section member, Health Care Technology and Decision Sciences

2007 – 2008 President, Society for Medical Decision Making

2007 Co-director, Think Tank Meeting: Preventing Tomorrow's Sudden Cardiac Death Today: Dissemination of effective therapies for sudden cardiac death prevention

2008 – 2009 Immediate Past President, Society for Medical Decision Making

2008 – 2009 Nominations Chair, Society for Medical Decision Making

2009 Co-director, Think Tank Meeting: Sudden Cardiac Arrest Thought Leadership Alliance

2009 – 2013 CTSA, Strategic Goal - 4B Comparative Effectiveness Workgroup, Duke University Representative

2009 – 2014 CERTS, comparative effectiveness special interest group member

2009 – 2014 CERTS, health economics special interest group member

2009 – 2013 Advisory board, Tools for Economic Analysis of Patient Management Interventions in Heart Failure (Shelby Reed R01)

2009 – 2013 Editorial Board, *Medical Decision Making*

2010 Co-director, Think Tank Meeting: Sudden Cardiac Arrest Thought Leadership Alliance

2010 – 2014 Awards Committee, Society for Medical Decision Making

2012 – present Policy Committee, Society for Medical Decision Making

2012 – 2016 Co-chair, Second Panel on Cost Effectiveness in Health and Medicine

2014 NIH AIDS, Clinical Studies, & Epidemiology (ACE) Study Section

2014 – 2015 SMDM Nominations Committee

2014 Patient Centered Outcomes Research Institute, Hepatitis C Stakeholder Workshop, Breakout Session Lead

2014 – present DCRI Women Faculty/Fellows Group, Leaders

2015 CME Reviewer, PCORI Methodology Report and Methodology Standards

2016 – present SMDM, Nominations Committee
 2016 – present International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force Member, Value of Information Analysis for Research Decisions: Emerging Good Practices.
 2017 – present SMDM, Strategic Plan Implementation Design Team Lead (Clinical and Health Stakeholder Engagement)
 2017 – present Triangle Women in STEM Initiative, Career Advancement Focus Working Group
 2017 – present Evidence-based Practice Center Methods Workgroup co-Lead (Health System Delivery)

Professional memberships:

Member, Society for Medical Decision Making
 Member, International Society for Pharmacoeconomics and Outcomes Research
 Member, AcademyHealth
 Member, American Public Health Association

Teaching responsibilities including continuing education:

2016 “Secondary Data Analysis” Clinical Research Training Program (CRTP) 242, “Principles of Clinical Research” (Duke University, Durham NC)
 2015 “Involving Stakeholders in Research” Clinical Research Training Program (CRTP) 242, “Principles of Clinical Research” (Duke University, Durham NC)
 2015 “Secondary Data Analysis” Clinical Research Training Program (CRTP) 242, “Principles of Clinical Research” (Duke University, Durham NC)
 2014 “Involving Stakeholders in Research” Clinical Research Training Program (CRTP) 242, “Principles of Clinical Research” (Duke University, Durham NC)
 2014 “Secondary Data Analysis” Clinical Research Training Program (CRTP) 242, “Principles of Clinical Research” (Duke University, Durham NC)
 2013 “Secondary Data Analysis” Clinical Research Training Program (CRTP) 242, “Principles of Clinical Research” (Duke University, Durham NC)
 2011 Instructor, “Decision Models” Duke Fuqua School of Business, Master of Management in Clinical Informatics, Duke University, Durham, NC.
 2010 “Introduction to medical decision-making and decision analysis” Department of Veterans Affairs Health Economics Resource Center Course in Health Economics, Menlo Park, CA.
 2009 “Secondary Data Analysis” Clinical Research Training Program (CRTP) 242, “Principles of Clinical Research” (Duke University, Durham NC)
 2009 “Introduction to medical decision-making and decision analysis” Department of Veterans Affairs Health Economics Resource Center Course in Health Economics, Menlo Park, CA.
 2008 “Secondary Data Analysis” Clinical Research Training Program (CRTP) 242, “Principles of Clinical Research” (Duke University, Durham NC)
 2007 “Secondary Data Analysis” Clinical Research Training Program (CRTP) 242, “Principles of Clinical Research” (Duke University, Durham NC)
 2007 “Introduction to medical decision-making and decision analysis” Department of Veterans Affairs Health Economics Resource Center Course in Health Economics, Menlo Park, CA.

- 2006 “Secondary Data Analysis” Clinical Research Training Program (CRTP) 242, “Principles of Clinical Research” (Duke University, Durham NC)
- 2006 “Introduction to medical decision-making and decision analysis” Department of Veterans Affairs Health Economics Resource Center Course in Health Economics, Menlo Park, CA.
- 2005 “Basics of Decision Analysis” (short course) Twenty Seventh Annual Meeting, Society for Medical Decision Making, San Francisco, CA
- 2005 “Introduction to medical decision-making and decision analysis” Department of Veterans Affairs Health Economics Resource Center Course in Health Economics, Menlo Park, CA.
- 2004 “Policy Models: Practical Strategies for Tackling the Challenges” (short course) Twenty Sixth Annual Meeting Society for Medical Decision Making, Atlanta, GA
- 2000 – 2002 Co-instructor, Economics 332, "Analysis of Costs, Risks, and Benefits in Health Care" (Stanford University, Stanford, CA).
- 2000 – 2003 "Introduction to Medical Decision Making" Stanford Medical Informatics Short Course. Stanford University, Stanford CA.
- 2000 “Medical informatics tools for clinical-practice guideline development" (short course) Twenty-second Annual Meeting, Society of Medical Decision Making; Cincinnati, OH.
- 1999 "Workshop on implementing cost-effectiveness analyses", Economics 332, "Analysis of Costs, Risks, and Benefits in Health Care" (Stanford University, Stanford, CA).
- 1999 "Introduction to Markov models for medical decision making", Economics 332, "Analysis of Costs, Risks, and Benefits in Health Care" (Stanford University, Stanford, CA).
- 1999 "Automated creation of clinical-practice guidelines from decision models", Medical Information Sciences 210, "Computer Applications in Medical Care" (Stanford University, Stanford, CA).
- 1999 “Medical informatics tools for clinical-practice guideline development" (short course) Twenty-first Annual Meeting, Society of Medical Decision Making; Reno, NV.
- 1997 “Automated creation of clinical-practice guidelines from decision models” Medical Information Science Short Course, Stanford University; Stanford, CA.
- 1997 “The use of medical informatics to develop and implement clinical-practice guidelines" (short course) Nineteenth Annual Meeting, Society of Medical Decision Making; Houston, TX
- 1996 Teaching Assistant to Edward Shortliffe M.D., Ph.D. for “Computer-Assisted Medical Decision Making” (Stanford University, Stanford, CA).
- 1995 Teaching Assistant to Larry Fagan M.D., Ph.D. (Associate Director, Medical Information Sciences Program) for “Computer Applications in Medical Care” (Stanford University, Stanford, CA).

Invited lectures and presentations:

1. “A computer-based interview to identify HIV risk behaviors and to assess patient preferences for HIV-related health states” Eighteenth Annual Symposium on Computer Applications in Medical Care; Washington DC; October 1994.
2. “Prevention of sudden cardiac death: a probabilistic model for decision support” Nineteenth Annual Symposium on Computer Applications in Medical Care; New Orleans, Louisiana, October, 1995.

3. "Reflecting uncertainty in cost-effectiveness analysis" Section on Medical Informatics Seminar Series, Stanford University, Stanford, California, October, 1996.
4. "Presentation and explanation of medical decision models using the World Wide Web" Annual Fall Symposium, American Medical Informatics Association; Washington DC, October, 1996.
5. "Cost effectiveness of monitored isoniazid prophylaxis for low risk tuberculin reactors over age 35" (poster presentation) Nineteenth Annual Meeting, Society for Medical Decision Making; Houston, Texas, October, 1997.
6. "Distributed dynamic decision support using a web-based interface for prevention of sudden cardiac death" Nineteenth Annual Meeting, Society for Medical Decision Making; Houston, Texas, October, 1997.
7. "Cost effectiveness of implantable cardiac defibrillators (ICDs) after myocardial infarction (MI)." Nineteenth Annual Meeting, Society for Medical Decision Making; Houston, Texas, October, 1997.
8. "Automated creation of clinical-practice guidelines from decision models" Department of Ambulatory Care and Prevention, Harvard Medical School, February 1998.
9. "Automated creation of clinical-practice guidelines from decision models" VA Puget Sound Health Care System, HSR&D Field Program and the Department of Health Services, University of Washington, April 1998.
10. "Development and pilot evaluation of automated computer-based creation of site-specific clinical-practice guidelines from decision models." (poster presentation) Twentieth Annual Meeting, Society for Medical Decision Making; Boston, Massachusetts, October, 1998.
11. "Design and implementation of a computer-based system to annotate decision models for use in guideline development." Twentieth Annual Meeting, Society for Medical Decision Making; Boston, Massachusetts, October, 1998.
12. "Cost effectiveness of implantable cardioverter defibrillators and amiodarone after myocardial infarction." (poster presentation) American College of Cardiology 48th Annual Scientific Session; New Orleans, LA, March 1999.
13. "Use of decision models to extrapolate results from clinical trials: Cost effectiveness of the implantable cardioverter defibrillator (ICD). Twenty-first Annual Meeting, Society for Medical Decision Making, Reno, Nevada, October, 1999.
14. "Automated Development of Clinical-Practice Guidelines from Decision Models" Agency for Health Care Policy and Research Methods Conference, Arlington, Virginia, October 1999.
15. "Automated creation of clinical-practice guidelines from decision models" Stanford Department of Health Research and Policy Research in Progress Seminar; Stanford, CA: March 2000.
16. "Development of interactive web-based guidelines for prevention of sudden cardiac death" (poster presentation) North American Society for Pacing and Electrophysiology 21st Annual Scientific Meeting; Washington D.C.; May, 2000.
17. "Decision modeling for cost-effective analysis of diagnostic strategies" Department of Public Health Sciences. London, England: August 2000.
18. "Publishing web-based guidelines using interactive decision models". (poster presentation) American Medical Informatics Association Annual Fall Symposium; Los Angeles, CA; November 2000.
19. "Development and dissemination of computer-based guidelines to prevent sudden cardiac death" Stanford

Department of Medicine Research Conference; Stanford, CA, December 2000.

20. "Cost effectiveness of a PET-FDG diagnostic strategy before hepatic resection for colorectal metastases" Stanford Department of Health Research and Policy Research in Progress Seminar; Stanford, CA: February 2001.
21. "Prevention of sudden cardiac death: Cost effectiveness of available treatments and of customizable computer-based guidelines" Department of Health Research and Policy: Biostat Workshop; Stanford, CA: February 2001.
22. "Translating evidence into clinical practice: Using decision models for guideline development and dissemination" Stanford Medical Informatics: Research Colloquia; Stanford, CA: April 2001.
23. "Introduction to medical decision making and decision analysis" Veterans Affairs Health Economics Resource Center Teleconference Series; Menlo Park, CA: May 2001.
24. "Cost effectiveness of a potential human papillomavirus vaccine" Stanford Department of Health Research and Policy Research in Progress Seminar, Stanford, CA: May 2001.
25. "Use of decision models in clinical-practice guideline development" (poster presentation) Academy for Health Services Research and Health Policy Annual Meeting, Atlanta, GA; June 2001.
26. "Cost effectiveness of a potential human papillomavirus vaccine" 19th International Papillomavirus Conference, Florianopolis, Brazil, September 2001.
27. "Cost effectiveness of a potential human papillomavirus vaccine" Twenty-third annual meeting, Society for Medical Decision Making; San Diego, California; October 2001.
28. "Implementing prevention guidelines: Practicing amid conflicting recommendations" Preventive Medicine 2002; San Antonio, Texas; February 2002.
29. "Cost effectiveness of a potential human papillomavirus vaccine" Second International Cervical Cancer Meeting; Houston, Texas; April 2002.
30. "Cost-effectiveness of vaccinating college freshmen against meningitis" Stanford Department of Health Research and Policy Research in Progress Seminar, Stanford CA, June 2002
31. "Evaluation of potential human papillomavirus vaccine rollout strategies using a dynamic transmission model" Stanford Department of Health Research and Policy Research in Progress Seminar, Stanford CA, June 2002
32. "Health Services Research 102: Integrating medical informatics and health services research" Stanford Department of Health Research and Policy Research in Progress Seminar, Stanford CA, July 2002.
33. "Automated customization of recommended strategies for management of solitary pulmonary nodules" (poster presentation) Twenty-fourth annual meeting, Society for Medical Decision Making; Baltimore, Maryland; October 2002.
34. "Automated and evidence-based site-specific guidelines for HIV screening" (poster presentation) Twenty-fourth annual meeting, Society for Medical Decision Making; Baltimore, Maryland; October 2002.
35. "Cost effectiveness of positron emission tomography (PET) before hepatic resection for colorectal metastases" Twenty-fourth annual meeting, Society for Medical Decision Making; Baltimore, Maryland; October 2002.
36. "Cost effectiveness of HIV screening in acute care settings in the era of highly active antiretroviral therapy" Twenty-fourth annual meeting, Society for Medical Decision Making; Baltimore, Maryland; October 2002.

37. "Introduction to medical decision making and decision analysis" Veterans Affairs Health Economics Resource Center Teleconference Series; Menlo Park, CA: August 2003.
38. "Effect of transmission on the cost effectiveness of screening for HIV" Twenty-fifth annual meeting, Society for Medical Decision Making; Chicago, Illinois, October 2003.
39. "Potential cost effectiveness of genetic screening for sudden cardiac death" Twenty-fifth annual meeting, Society for Medical Decision Making; Chicago, Illinois, October 2003.
40. "Cost effectiveness of photodynamic therapy for high-grade dysplasia in barrett's esophagus" Twenty-fifth annual meeting, Society for Medical Decision Making; Chicago, Illinois, October 2003.
41. "Potential cost effectiveness of genetic screening for sudden cardiac death" Research Conference, Duke Clinical Research Institute; Durham, NC, April 2004.
42. "Evaluating HPV Vaccination Programs" Modeling Outcomes for HPV Vaccine sponsored by the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP); Atlanta, Georgia, September 2004.
43. "Cost effectiveness of the implantable cardioverter defibrillator in the MADIT-II population" Twenty-sixth annual meeting, Society for Medical Decision Making; Atlanta, Georgia, October 2004.
44. "Cost effectiveness of HIV screening in the elderly" Twenty-sixth annual meeting, Society for Medical Decision Making; Atlanta, Georgia, October 2004.
45. "ALCHEMIST-FRONTIER: a web-based application to facilitate analysis of decision models comparing multiple possible sequences of diagnostic tests." Twenty-sixth annual meeting, Society for Medical Decision Making; Atlanta, Georgia, October 2004.
46. "Introduction to medical decision making and decision analysis" Veterans Affairs Health Economics Resource Center Teleconference Series; Menlo Park, CA: May 2005.
47. "Cost effectiveness of imaging tests and surveillance strategies for colorectal cancer" Digestive Disease Weekly. Chicago, IL. May 2005.
48. "Cost effectiveness of screening for HIV" 2005 National HIV Prevention Conference, June 12-15, 2005, Atlanta, Georgia
49. "Imaging tests and surveillance strategies for colorectal cancer: Is computed tomographic colonography a cost-effective option?" Twenty-seventh annual meeting, Society for Medical Decision Making; San Francisco, California, October 2005
50. "Preference-based decision making to guide testing for breast cancer genes" Twenty-seventh annual meeting, Society for Medical Decision Making; San Francisco, California, October 2005
51. "Evaluating Human Papillomavirus Vaccination Programs" Centers for the Disease Control and Prevention, HPV Modeling Review Meeting; Atlanta, Georgia, December 2005
52. "Evaluating Human Papillomavirus Vaccination Programs" GlaxoSmithKline, HPV Transmission Model Steering Committee Meeting; Surrey, United Kingdom, January 2006
53. "Inappropriate Shocks Reduce Implantable Cardioverter Defibrillator Cost Effectiveness" Heart Rhythm Society Annual Meeting, Boston, Massachusetts, May 2006
54. "Introduction to medical decision making and decision analysis" Veterans Affairs Health Economics Resource Center Teleconference Series; Menlo Park, CA: July 2006.

55. "Policy and practice based on best available evidence: The role of systematic reviews: A case study of implantable defibrillators and cost" North American Conference on Systematic Reviews, Cochrane Collaboration; Baltimore, MD, July 2006
56. "Devices: Controlling the Cost" Heart Failure Society 10th Annual Meeting, Seattle, Washington, September 2006.
57. "Modeling the Long-Term Clinical Impact of HPV Vaccination in the US: The Impact of Herd Immunity on Cervical Cancer and Pre-Cancerous Lesions" 23rd International Papillomavirus Conference, Prague, Czech Republic, September 2006
58. "Cost Effectiveness of Screening with Streamlined Counseling" Twenty-eighth annual meeting Society for Medical Decision Making; Cambridge Massachusetts, October 2006.
59. "Can Screening ever be a Feasible Method for Ovarian Cancer Mortality Reduction?" Twenty-eighth annual meeting Society for Medical Decision Making; Cambridge Massachusetts, October 2006.
60. "Effectiveness and Cost Effectiveness of HPV Vaccination Programs: A Decision Analytic Approach" HPV Vaccine Masters' Class #2 – The Economics of HPV Prevention Programs; Quebec City, Quebec, January 2007
61. "Cost Effectiveness of the ICD in Primary Prevention of Sudden Cardiac Death" Heart Rhythm Scientific Sessions, Denver CO, May 2007
62. "Using hybrid (dynamic transmission and cohort) models to evaluate HPV vaccine implementation strategies" 4th Health Technology Assessment International Annual Meeting, Barcelona, Spain, June 2007.
63. "Modeling the Impact of Vaccination against Cervical Cancer until Steady State: Cost-Effectiveness and Reduction in Outcomes" 4th Health Technology Assessment International Annual Meeting, Barcelona, Spain, June 2007.
64. "Introduction to medical decision making and decision analysis" Veterans Affairs Health Economics Resource Center Teleconference Series; Menlo Park, CA: July 2007.
65. "Potential Impact of a Bivalent HPV Vaccine: Effectiveness and Cost Effectiveness of Vaccination" 17th ISSTD International Society for STD Research 10th IUSTI World Congress Seattle, WA, August 2007.
66. "Modeling the Potential Cost-Effectiveness of Adding a Novel STAT-C Agent to Current Standard Therapy in Patients With Genotype 1 Chronic Hepatitis C Infection" Twenty Ninth Annual Meeting of the Society for Medical Decision Making, Pittsburgh, PA October 2007
67. "Cost Effectiveness of Strategies to Improve HIV Testing and Receipt of Results" Twenty Ninth Annual Meeting of the Society for Medical Decision Making, Pittsburgh, PA October 2007
68. "Effect of HPV Vaccine Characteristics and Implementation Strategies on Incidence of Disease" Twenty Ninth Annual Meeting of the Society for Medical Decision Making, Pittsburgh, PA October 2007
69. "Decision Analytic Modeling of Chronic Diseases: Towards Effective and Cost Effective Evidence-Based Care" Decision Sciences Seminar, Fuqua Business School, Duke University, Durham, NC, January 2008.
70. "Evaluating Costs and Benefits of Human Papillomavirus Vaccination Programs" Division of Infectious Diseases, Grand Rounds, Duke University, Durham NC, April 2008.
71. "Use of Bayesian Techniques in Randomized Clinical Trials: A Centers for Medicare and Medicaid Case Study" Department of Statistics Research Seminar, Duke University, Durham NC, April 2008.

72. "SMDM's Policy Impact: We're 30...What Do We Have to Show For It?: President's Address" Annual Meeting Society for Medical Decision Making, Philadelphia PA, October 2008
73. "Is ICD therapy cost effective?" National Cardiovascular Disease Epidemic: East Coast Chautauqua. Miami, Florida, November 2008
74. "Use of Bayesian Techniques in Randomized Clinical Trials: A Centers for Medicare and Medicaid Case Study" Centers for Medicare and Medicaid/ Agency for Healthcare Research and Quality Seminar, Rockville, MD, November 2008.
75. "Cost effectiveness of HIV screening" Research Conference, Duke Clinical Research Institute; Durham, NC, October 2008
76. "'Decision Analytic Modeling of Chronic Diseases: Towards Effective and Cost Effective Evidence-Based Care.'" North Carolina State University Healthcare Engineering Seminar, Raleigh NC, April 2009
77. "Use of Bayesian Techniques in Randomized Clinical Trials: A Centers for Medicare and Medicaid Case Study" Medicare Evidence Development & Coverage Advisory Committee, Baltimore, MD, June 2009
78. "Bayesian Methods in RCTs: ICD Therapy for the Prevention of Sudden Cardiac Death" Annual Meeting Society for Medical Decision Making, Hollywood, CA, October 2009.
79. "The Duke Evidence-based Practice Center" Durham VA HSR&D Research Conference, December 2009
80. "Modeling Costs and Benefits of HPV Vaccination Implementation Strategies" SAMSI Program on Stochastic Dynamics, January 2010
81. "Decision Analytic Modeling of Chronic Diseases: Towards Effective and Cost Effective Evidence-Based Care" University of Pittsburgh Center for Research on Health Care Seminar Series, March 2010
82. "Comparative Effectiveness at the DCRI", DCRI Research Conference, April 2010
83. "Using Value of Information to Prioritize Future Research: A Case Study" AHRQ 2010 Annual Conference, September 2010.
84. "Duke Evidence-Based Practice Center (EPC): Cardiovascular Disease Evidence Synthesis" AHRQ DEcIDE Cardiovascular Consortium Meeting, June 2011
85. "Assembling a Systematic Review Team: Balancing Expertise and Potential Conflicts of Interest" AHRQ 2011 Annual Conference, September 2011.
86. "Preventing Sudden Cardiac Death: Harnessing the Power of Decision Analysis, Bayesian Techniques, and Clinical Trials" AHRQ Annual Conference, September 2011.
87. "Comparative Effectiveness Research and the U.S. Effective Healthcare Program" University of York Centre for Health Economics Economic Evaluation Seminar, October 2011.
88. "Comparative Effectiveness Research and the U.S. Effective Healthcare Program" Warwick Medical School, Division of Health Sciences Seminar Series, November 2011.
89. "EPC Pearl: Herding Cats...Or Investigators" EPC Fall Meeting, November 2011
90. "Patient Centered Outcomes Research Institute" Duke Comparative Effectiveness Research Seminar, December 2011
91. "Comparative Effectiveness Research" 2013 Duke/BMS Spring Series Meeting, May 2013

92. “Future Research Prioritization: Helping PCORI Define Their Research Agenda” Duke Comparative Effectiveness Research Seminar, February 2014
93. “Comparative Effectiveness Research” 2014 Duke/BMS Spring Series Meeting, May 2014
94. “Training Outcomes Researchers: Critical Gaps and Needs” NHLBI Center for Cardiovascular Outcomes Research Think Tank Meeting, June 2014
95. “Using Evidence-Based Decision Models to Inform Patients, Providers, and Policymakers”, UNC Cancer Outcomes Research Program Breakfast Seminar, June 2014
96. “Training Outcomes Researchers: Critical Gaps and Needs” DCRI Research Conference, December 2014
97. “Using Evidence-Based Decision Models to Inform Patients, Providers, and Policymakers” Pharmaceutical Outcomes Research and Policy Program, University of Washington, February 2015
98. “Making an Impact” University of North Carolina at Chapel Hill Health Policy and Management Seminar, June 2015
99. “Future Research Prioritization: Helping PCORI Define Their Research Agenda” Kaiser Permanente Research August 2015
100. “Using Evidence to Inform Patients, Providers, and Policymakers” Durham VA HSR&D November 2015
101. “Primer on Value of Information Analysis” Office of Women’s Health, Department of Health and Human Services, Washington DC, May 2016
102. “Synthesizing Evidence – Informing Decision Making” John Hopkins School of Public Health, Department of Health Policy and Management, Baltimore July 2016.
103. “Synthesizing Evidence – Informing Decision Making”. Duke Clinical Research Institute Signature Series May 2016
104. “Recommendations of the Second Panel on Cost Effectiveness in Health and Medicine” Society for Medical Decision Making, Vancouver BC Canada October 2016
105. “Recommendations of the Second Panel on Cost Effectiveness in Health and Medicine” National Academy of Sciences, Washington DC December 2016
106. “Efficiency and Ethics” Duke Medical School, Global Health & Health Policy Week, December 2016
107. “Recommendations of the Second Panel on Cost Effectiveness in Health and Medicine”, Keynote presentation, Fourth Annual Global Health Economics Colloquium, University of California San Francisco, February 2017
108. “Synthesizing Evidence and Cost-Effectiveness Analyses to Inform Value-Based Frameworks” Duke Margolis Center for Health Policy Research in Progress Seminar, February 2017

Undergraduate and Graduate Student Supervision:

- Otto Lin MD, MS, Health Research and Policy, Stanford University (June 2001)
 Masters Thesis “Screening for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis: efficacy and cost effectiveness”
- Jenny Silverman BA, Economics, Stanford University (June 2002)
 Senior Honors Thesis “Genetic testing for breast and ovarian cancer”

Awarded Stanford University Firestone Medal for Excellence in Undergraduate Research (1 of 27 awardees from 1,736 undergraduates)

Awarded 2nd prize, Lee Lusted National Student Research Competition for abstract entitled “Cost effectiveness of assessing patient preferences for treatment of breast and ovarian cancer susceptibility”, Twenty-fourth Annual Meeting, Society for Medical Decision Making (October 2002)

George C. Scott PhD, Medical Informatics, Stanford University (November 2002)
 Doctoral Dissertation “Using decision models to automate and individualize interactive decision support for patients”

Allison Widman BA in Human Biology, Stanford University (June 2003)
 Senior Honors Thesis “The cost-effectiveness of dose-dense versus conventionally scheduled combination chemotherapy as postoperative adjuvant treatment for node-positive primary breast cancer”
 Awarded Stanford University Firestone Medal for Excellence in Undergraduate Research (1 of 29 awardees from 1,865 undergraduates)

Rohini Vij MD, MS, Health Research and Policy, Stanford University (June 2003)
 Masters Thesis “Cost-effectiveness of photodynamic therapy for high-grade dysplasia in barrett’s esophagus”

Al Taira BA, Medical Student, Stanford University (June 2005)
 Medical Scholars Project “Evaluation of potential human papillomavirus vaccine rollout strategies using a disease-transmission model”

Christy Dosiou MD, Epidemiology, Endocrine Fellow (June 2006)
 Masters Thesis “Screening pregnant women for autoimmune thyroid disease: A cost-effectiveness analysis”

Eran Bendavid MD, Health Research and Policy, Stanford University (June 2009)
 Masters Project "Cost effectiveness of HIV monitoring strategies in resource-limited settings"

Swati Tole MD, Health Research and Policy, Stanford University (June 2009)
 Masters Project "The cost effectiveness of HIV screening in a resource limited country: a model of screening in Russia"

Sam Galhenage, M.D., Clinical Research Fellow, GI/Hepatology Division, Duke University (December 2007)
 Project "Cost Effectiveness of VX-950 Use in Chronic Hepatitis C Virus Therapy"

David Holland M.D. Clinical Fellow, Division of Infectious Diseases, Duke University (2012)
 Project “The cost-effectiveness of various strategies for treating latent tuberculosis infection due to multiple-drug resistant and extensive-drug resistant strains”
 Awarded Duke’s Barton F. Haynes Early Career Grant Awardees in 2009
 Co-Faculty Advisor for K-01 Career Development Award #1K01AI083782-01 “Mathematical modeling in clinical trials of tuberculosis therapeutics.”

Nancy Allen Lapointe PharmD, KM1 CER Scholar (June 2014)
 Project “Comparison of Pharmacologic Rhythm Control Versus Rate Control for Atrial Fibrillation in Patients < 65 Years of Age”

Remy Coeytaux MD, PhD K18 Mid-Career Award AHRQ (July 2015)
 Project “Assessment of a Personalized Health Care Intervention for Chronic Daily Headache”

Emily Zeitler MD, T32 Cardiovascular Fellowship Clinical Research Training Grant (July 2016)
 Methodology mentor across diverse projects.

Daniel Friedman MD, T32 Cardiovascular Fellowship Clinical Research Training Grant (July 2017)
 Methodology mentor across diverse projects.

Megan Clowse MD, MPH K18 Mid-Career Award AHRQ (July 2017)
 Project “Optimizing Lupus Management in Pregnancy”

Areas of research interests:

1. Comparative effectiveness research
2. Evidence-based decision models
3. Value-of-information analyses
4. Evaluation of prevention, treatment, and management strategies for chronic disease
5. Systematic reviews of the literature
6. Translation of evidence into formats/tools to aid patients, providers, and policymakers in their decision making process

7. Population health
8. Value assessment frameworks

External support – gifts, grants, and contracts:

Active

1. Power of Bayesian Methods, RCTs, and Decision Models to Inform CRT Uncertainties
1R01HL131754-01A1

Principal Investigator: Gillian D. Sanders Ph.D.

National Heart, Lung, and Blood Institute

Project Period: 12/15/2016 – 11/30/2020

Total Costs: \$2,650,807

Our long-term goal is to enhance the ability of the NHLBI to provide evidence-based decisionmaking tools to aid patients, providers, and policymakers in the use of CRT for the treatment of HF. To achieve this overall goal, we have four specific aims (SA): (1) To work with diverse stakeholders to identify and prioritize timely clinical and policy questions regarding the comparative effectiveness of CRT; (2) To develop a generalizable decision modeling framework for the treatment of HF; (3) To use Bayesian statistical techniques to devise a model for predicting patient and population health and economic outcomes; and (4) To combine the framework from SA#2, the Bayesian model from SA#3, and patient level data from existing RCTs and registries, to explore high-priority questions identified in SA#1.

2. Systematic Review Update for PCORI – Stroke Prevention in Atrial Fibrillation

HHS290201500004I-Task Order 9

Principal Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality/Centers for Medicare and Medicaid Services

Project Period: 4/14/2017-2/2/2018

Total Costs: \$255,000

To perform as part of the EPC program a systematic review on stroke prevention in patients with atrial fibrillation.

3. Value of Information Analysis: Diabetes Treatment

DukeIDIQ03.01.14 (VOI Analysis)

Principal Investigator: Gillian D. Sanders Ph.D.

Patient-Centered Outcomes Research Institute

Project Period: 2/10/2017-8/16/2017

Total Costs: \$118,861.40

To use value-of-information (VOI) analysis to determine the added value to society of evidence resulting from the conduct of a trial that compares three drugs used as second-line treatments for type 2 diabetes mellitus when glycemic control cannot be maintained with metformin alone.

4. Evidence-based Practice Centers (EPC) V (HHS290201500004I)

Principal Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 12/03/2014-11/30/2019

Current Costs: Task Order Dependent

EPCs will work with various partners and stakeholders to synthesize evidence on a variety of health care delivery and clinical areas. EPCs must be able to address both healthcare delivery as well as clinical topics across the range of clinical specialty care areas that address partner needs. EPCs may be asked to focus on traditional therapeutics as well as complementary, alternative, nutritional, and other emerging areas such as genomics and may span from preventative services to implementation of medical devices.

5. Screening and Treatment of Depression in Post MI Patients

Principal Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality/Centers for Medicare and Medicaid Services

Project Period: 1/26/2016-3/2/2017

Total Costs: \$480,000

To perform as part of the EPC program a systematic review on diagnosis and treatment of depression in patients with acute coronary syndrome.

6. Optimizing Health Outcomes in Patients with Symptomatic Aortic Valve Disease (CER-1306-04350)

Principal Investigator: Matthew Brennan MD

Co-Investigator: Gillian D. Sanders Ph.D

Patient-Centered Outcomes Research Institute

Project Period: 05/01/2014-04/30/2017

Total Costs: \$497,544

The overarching goal of this study is to develop a broadly applicable patient-centered paradigm for the individualized treatment of medical illness.

Past

1. Cardiac Arrhythmia Patient Outcomes Research Team (PORT)

Principal Investigator: Mark A. Hlatky MD

Decision Analyst: Gillian D. Sanders, Ph.D.

Agency for Health Care and Policy Research (HS08362)

Period: 08/01/94 – 11/30/00

The major goal of this project is to develop a comprehensive decision model for screening and treatment of patients at risk for sudden cardiac death.

2. An Economic Analysis of a Potential Vaccine Against *Coccidioides Immitis*

Principal Investigator: Douglas K. Owens MD, MS

Co-Investigator: Gillian D. Sanders, Ph.D.

California Department of Health Services (via the Valley Fever Vaccine Project)

Period: 05/01/99 – 10/30/99

The major goal of this project is to develop a cost effectiveness analysis of a *C. immitis* vaccine that is currently under development.

3. A cost-benefit analysis of the fortification of grain with vitamin D and calcium for the prevention of osteoporosis

Principal Investigator: Gillian D. Sanders, Ph.D.

Iris F. Litt M.D. Fund, Stanford University

Period: 6/1/00-5/31/01

The major goal of this project is to examine the effectiveness of fortifying grain with vitamin D and calcium for the prevention of osteoporosis.

4. The development of a computer simulation model for the evaluation of diagnostic guidelines

Principal Investigator (Stanford Subcontract): Gillian D. Sanders, Ph.D.

Guy's, King's, and St. Thomas School of Medicine, London

Period: 04/01/99 – 03/31/2000

The major goal of the prime grant (Michael Maisey MD, Principal Investigator) is to develop a modeling capacity using computer simulation to assess the clinical and cost effectiveness of different diagnostic guidelines for the investigation of common clinical situations. The goal of the Stanford subcontract is to develop a model to evaluate the cost effectiveness of a PET-FDG strategy before hepatic resection for colorectal metastases.

5. Economic Evaluation of the Wearable Cardioverter Defibrillator

Principal Investigator: Gillian D. Sanders Ph.D.

Berlex Laboratories, Inc.

Period: 10/01/00 – 4/30/01

The goal of this project is to evaluate the cost effectiveness of a wearable cardioverter defibrillator in post-myocardial infarction patients who have depressed left ventricular function.

6. Cost Effectiveness of and HPV Vaccine for Cervical Cancer

Principal Investigator: Gillian D. Sanders PhD
Stanford Cancer Council
Period: 10/1/00 - 9/30/01

The major goal of this project is to evaluate the cost effectiveness of a potential HPV vaccine to prevent cervical cancer

7. Cost Effectiveness of Genetic Tests in Coronary Artery Disease

Principal Investigator: Gillian D. Sanders Ph.D.
National Institute on Aging
Period: 8/1/02-7/31/03

The goal of this proposed research is to develop a model of coronary disease in the elderly that incorporates current treatment and prevention recommendations to evaluate the cost-effectiveness of genetic profiling in coronary disease management.

8. Cost Effectiveness of HIV Screening and Treatment in the Elderly

Co-Principal Investigator: Gillian D. Sanders Ph.D.
National Institute of Aging
Period: 10/1/02 – 9/30/03

The goal of this project is to address the cost effectiveness of both treatment and screening in the elderly in a variety of practice settings

9. Identification of HIV Infection Among Veterans

Principal Investigator: Douglas K. Owens MD, MS
Co-Investigator: Gillian D. Sanders Ph.D.
Department of Veterans Affairs
Period: 10/1/99 – 9/31/03

The major goals of this project are to examine current testing practices for HIV in the VA and to develop a national guideline for screening for HIV in the VA.

10. Prospective Comparison of Colonic Imaging Tests (Economic Substudy)

Principal Investigator: Don C. Rockey MD
Decision Analyst: Gillian D. Sanders Ph.D.
National Cancer Institute
Period: 8/24/00-5/31/05

The goal of this project is to study the relative accuracy of air contrast barium enema, colonoscopy and virtual colonoscopy. In addition, we seek to perform analyses to determine how the tests are viewed by patients and to determine which is the most cost-effective approach for evaluation of patients with fecal occult blood, the major indication for colonic imaging.

11. 18-F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) Imaging in Patients with Solitary Pulmonary Nodules: Economic Study

Principal Investigator: Paul Barnett PhD
Decision Analyst: Gillian D. Sanders, Ph.D.
Department of Veterans Affairs, Cooperative Studies Program
Period: 06/01/98 – 12/31/05

The major goal of this project is to evaluate the cost effectiveness of PET scanning for the diagnosis of solitary pulmonary nodules.

12. Computer-Based Guidelines to Prevent Sudden Cardiac Death

Principal Investigator: Gillian D. Sanders Ph.D.
Agency for Healthcare Research and Quality
Period: 10/1/00 – 2/28/05

The major goal of this project is to extend our prior work on the automated creation of clinical-practice guidelines from evidence-based decision models, to create and validate a guideline based on the findings of the Cardiac Arrhythmia PORT, and to evaluate clinicians' use and satisfaction with the developed web-based guideline

system. The project aims to improve access to decision-making tools and to foster appropriate use of medical evidence by providing a link between clinical-practice guidelines and decision models.

13. Stanford-UCSF Evidence-Based Practice Center
Governing Council Member: Gillian D. Sanders Ph.D.
Agency for Healthcare Research and Quality
Period: 07/01/02 - 06/30/07

The goals of the contract are to provide an infrastructure for efficiently conducting systematic literature reviews, performing supplemental syntheses, and completing technology assessment and evidence reports of the highest quality.

14. Duke Evidence-Based Practice Center: ICD Registry
Principal Investigator: David B. Matchar MD
Co-Investigator: Gillian D. Sanders Ph.D.
Agency for Healthcare Research and Quality
Period: 11/15/04-2/15/05

The goal of the contract is to (1) review current ICD registries including the hypotheses and objectives, and how the data elements were constructed to collect relevant data, (2) propose a set of hypotheses that could be answered with a registry, and what data would be necessary to use the registry to investigate those hypotheses, (3) propose a set of data elements for the registry

15. Duke Evidence-Based Practice Center: General Registry
Principal Investigator: David B. Matchar MD
Co-investigator: Gillian D. Sanders Ph.D.
Agency for Healthcare Research and Quality
Period: 2/1/05-6/30/05

The goal of this contract is to determine what constitutes a successful and high-quality registry. In answering this question, this analysis will explore (1) For which problems are registries likely to be the best solution? (2) How should registries be designed? (3) How should the day-to-day operations of a registry proceed?

16. Duke Evidence-Based Practice Center: Genomics Tests for Ovarian Cancer Detection and Management
Principal Investigator: Evan Myers MD
Co-investigator: Gillian D. Sanders Ph.D.
Agency for Healthcare Research and Quality
Period: 10/1/2005-9/30/2006

Evidence report on the effectiveness and cost effectiveness of genomic tests for ovarian cancer detection and management

17. Making Better Decisions: Policy Modeling for AIDS and Drug Abuse
Principal Investigator: Douglas K Owens MD, MS
Co-investigator: Gillian D. Sanders Ph.D.
National Institute on Drug Abuse
Period: 7/1/02 – 6/30/07

The goal of this grant is to promote reasoned planning and policy making in the realm of HIV and substance abuse prevention via the development of mathematical and economic models.

18. Computerized Decision Support for Managing Lung Nodules
Co-Principal Investigator: Gillian D. Sanders PhD
National Cancer Institute
Period: 6/27/05-5/31/08

The goal of this grant is to develop ALCHEMIST-SPN, an interactive decision support system for management of patients with solitary pulmonary nodules, by linking a previously developed decision analytic model with the existing ALCHEMIST architecture for computer-based decision support. We will then validate the predictions and management recommendations generated by the ALCHEMIST-SPN decision model.

19. Improving HIV Screening by Nurse Rapid HIV Testing and Streamlined Counseling

Principal Investigator: Steve Asch MD
Co-investigator: Gillian D. Sanders PhD
Department of Veterans Affairs
Period: 1/1/2005-9/30/2007

The aims of this project are to determine if nurse-based screening, rapid HIV testing and streamlined counseling improve HIV screening rates in a VA facility and to determine the cost-effectiveness of these strategies

20. Effective and Cost Effective Use of Implantable Cardioverter Defibrillator in the Elderly

Principal Investigator: Gillian D. Sanders Ph.D.
Duke University Medical Center CERTS (Center for Education & Research on Therapeutics)
Agency for Healthcare Research and Quality
Period: 10/1/2006-9/30/2007

The aims of this project are (1) To synthesize existing data from the Duke Databank, recent clinical trials, and the published literature to explore the evidence supporting the use of ICDs in the elderly, and (2) To extend a previously developed decision model on the primary prevention of sudden cardiac to assess the effectiveness and cost effectiveness of ICD implantation in the elderly

21. Patient Reported Outcomes Measurement Information System (PROMIS)

Principal Investigator: Kevin P. Weinfurt Ph.D.
Co-Investigator: Gillian D. Sanders Ph.D.
National Institutes of Health
Period: 09/28/04 - 08/31/09

Specific aims of the Duke PROMIS project are (1) To develop options for integrating CAT into current and future data capture systems used in multicenter clinical trials, (2) To assess the readiness of sites in multicenter clinical trials to collect PRO data using CAT, (3) To conduct simulations to explore the costs and benefits of implementing different PRO data collection models in multicenter clinical trials, (4) To develop recommendations for incorporating CAT into current and future data capture systems used in multicenter clinical trials, and (5) To anticipate how the PROMIS Tool could be used in the context of daily electronic data collection methods.

22. Use of Bayesian Techniques in Randomized Clinical Trials: A CMS Case Study

Principal Investigator: Gillian D. Sanders Ph.D.
Agency for Healthcare Research and Quality
Period: 04/01/07-09/30/08

The goal of the proposed research will be to provide CMS with a general approach for assessing the use of Bayesian techniques in randomized clinical trials. To reach this goal we will have three specific aims: (1) To provide a synthesis of existing research regarding the advantages and disadvantages of Bayesian techniques in clinical trial design and analysis, (2) To explore Bayesian techniques in the CMS context through the specific clinical domain of the prevention of sudden cardiac death (SCD) and trials to determine the effective use of the implantable cardioverter defibrillator (ICD), (3) To use the findings of Specific Aim #1 and #2 to determine lessons learned specific to the CMS context and to provide for CMS general guidelines for evaluating the use of Bayesian techniques in future clinical studies

23. Optima: Tri-National Trial 1 (Options in Management with Anti-retrovirals): Economic Study

Decision Analyst: Gillian D. Sanders Ph.D.
Department of Veterans Affairs, Cooperative Studies Program
Period: 06/01/01 – 09/30/09

This is a tri-national (Canada, UK, USA) randomized controlled trial to determine the optimal management of patients with HIV infection for whom first and second-line highly active anti-retroviral therapy has failed. The economic study of the trial will look at the cost effectiveness of the different treatment strategies.

24. A randomized trial of remote monitoring of implantable cardioverter defibrillators against quarterly device interrogations in clinic

Principal Investigator: Sana Al-Khatib MD, MHS
Co-investigator: Gillian D. Sanders PhD
Medtronic-Duke University Strategic Alliance (MEDUSA)
Period: 07/01/06 – 06/30/2009

The central hypothesis of this study is that remote monitoring of ICDs, compared with quarterly device interrogations in clinic, will improve patients' outcomes and satisfaction and will reduce health care costs.

25. Characterization of Cardiac Arrhythmias in End Stage Kidney Disease Patients on Hemodialysis Using an Implantable Cardioverter Defibrillator

Principal Investigator: Sana Al-Khatib MD, MHS

Co-Investigator: Gillian D. Sanders Ph.D.

Medtronic, Inc

Period: 4/14/2009 – 4/14/2010

26. BCBS/BMP Subcontract – Technology Assessment – Bone Morphogenetic Protein

Principal Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 5/1/2009-12/31/2009

The objective of this technology assessment on BMP, specifically rh-BMP-7 (OP-1) and rh-BMP-2 (Infuse), is to assess the level of evidence supporting the on-label use of BMP and the level of evidence supporting the off-label uses of BMP in the Medicare population with a break down for the under 65 population and the 65 and older population.

27. Duke Cardiovascular CERTs

Principal Investigator: Eric Peterson MD

Co-Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Period: 09/01/07-08/31/11

This study aims to (1) Promote the optimization of professional society-led CV registries as national surveillance systems for evaluating and assuring the safety and effectiveness of CV therapeutics and devices in community based settings, (2) Identify specific barriers to the translation of CV drugs and device evidence into routine clinical practice as well as to those impeding patient adherence to effective CV therapeutics, (3) Develop and rigorously evaluate patient- and provider-based interventions designed to improve the safe, effective, and efficient acute and long-term use of CV therapies, (4) Widely disseminate those interventions found to be effective, and (5) Train the next generation of CV outcomes researchers.

28. Comparative Effectiveness of Antiretroviral Therapy for HIV in Patients with Comorbidities

Principal Investigator: Gillian D. Sanders PhD (Duke Subcontract, Stanford University)

National Institutes of Health

Project Period: 9/30/2009 - 9/29/2011

The goals of this study are to 1) Compare the effectiveness of initial antiretroviral therapy for treatment naïve HIV-infected individuals in the US based on age and co-morbidities; 2) Compare the effectiveness of advanced antiretroviral therapy for treatment-experienced HIV-infected individuals in the US based on age and co-morbidities; and 3) Perform a cost-effectiveness analysis of initial antiretroviral therapy for treatment-naïve HIV-infected individuals with co-morbidities.

29. Comparative Effectiveness of ACEIs and ARBs for Treating Essential Hypertension

Principal Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 7/1/2009-1/30/2011

The goal of this project is to update a previous systematic review of the comparative effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for treating essential hypertension. This project will summarize the evidence on the comparative long-term benefits and harms of ACEIs versus ARBs, focusing on their use for treating essential hypertension in adults.

30. Electronic Knowledge Management and Clinical Decision Support

Principal Investigator: David Lobach MD

Co-Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 09/25/2009 – 3/31/2011

To prepare an evidence report on electronic knowledge management and clinical decision support systems based on a comprehensive and systematic review of the scientific literature, other appropriate analyses, and extensive peer review of the draft report.

31. The Effectiveness of Disease-modifying Anti-rheumatic Drugs (DMARDS) in Children with Juvenile Idiopathic Arthritis (JIA)

Principal Investigator: Alex Kemper MD, MHS

Co-Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 08/1/2009 – 1/30/2011

To evaluate the comparative effectiveness of DMARDS compared with placebo, non-steroidal anti-inflammatory drugs (NSAIDs) and/or intra-articular corticosteroids in children with juvenile idiopathic arthritis.

32. CERTs Infrastructure Core (U19-HS021092)

Principal Investigator: Eric D Peterson MD, MS

Co-Investigator: Gillian D. Sanders Ph.D

Agency for Healthcare Research and Quality

Project Period: 09/30/2011-08/31/2016

Current Year Costs: \$537,375

The CERTs Research Center will provide an operational infrastructure of resources and coordination across research projects.

33. EPC: ECG Update

Principal Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 5/01/2011-03/01/2012

The purpose of the updated technology assessment is to summarize the available clinical and scientific evidence on ECG-based signal analysis technologies for evaluating patients with suspected coronary artery disease or acute coronary syndrome

34. EPC: Medical Test Guides

Principal Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 07/01/2011-02/15/2012

The purpose of this project is to develop online learning modules for the EPC Program Medical Test Guide which will be used for both CME credit and online training.

35. PCORI: Methods for Setting Priorities in Research

Principal Investigator: Gillian D. Sanders Ph.D.

Patient Centered Outcomes Research Institute

Project Period: 10/24/2011-3/15/2012

The goals are to update our recent systematic literature review on the use of VOI in research prioritization, with a special emphasis on identifying VOI applications in comparative effectiveness research, or VOI applications outside of a traditional cost-effectiveness analysis (CEA) framework; to summarize our experience of using modeling and VOI with stakeholders on two previous pilot projects for AHRQ; and to discuss alternative or complementary approaches to “traditional” VOI, in particular methods for incorporating patient preferences for attributes of health decisions that are not easily captured using the standard quality-adjusted life years (QALYs), such as conjoint analysis or discrete choice experiments

36. Heritable Disorders in Newborns and Children

Principal Investigator: Alex Kemper MD, MHS

Co-Investigator: Gillian D. Sanders Ph.D.

Altarum Institute/HRSA

Project Period: 08/19/2011-08/18/2012

This contract supports the External Evidence Review Workgroup (EERW) for the Secretary of Health and Human Services Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC). The EERW leads

systematic evidence review reports and presentations to the SACHDNC on conditions nominated for consideration for the Recommended Uniform Newborn Screening Panel, and will be developing an updated Condition Review Process manual to outline review methods and other relevant topics, such as the public health impact evaluation.

37. EPC: Postpartum Depression

Principal Investigator: Evan Myers MD, MPH

Co-Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 06/21/2011-09/24/2012

The purpose of this project is to perform a systematic review of screening tests for postpartum depression. We will focus on screening for postpartum depression, including consideration of different screening instruments, timings, and settings. Patient factors that may affect the performance of screening instruments are also considered.

38. EPC: Methods and Dissemination

Principal Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 09/01/2007-08/31/2012

To support the production of quality evidence reports that can be used and understood by appropriate stakeholders, the EPC shall commit adequate time and resources to advancing the methodology of systematic review.

39. EPC: Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer

Principal Investigator: Evan Myers MD, MPH

Co-Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 09/10/2010-09/30/2012

A study on the risks and benefits of oral contraceptives for the primary prevention of ovarian cancer, and furthermore quantify the risk-benefit ratio and identify research gaps.

40. EPC: Medical Test Guides

Principal Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 07/01/2011-06/30/2012

The purpose of this project is to develop online learning modules for the EPC Program Medical Test Guide which will be used for both CME credit and online training.

41. Comprehensive EPC Comparative Effectiveness Reviews for Effective Health Care

Principal Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 10/26/2009-10/25/2012

To serve within a core group of EPCs to focus on a comprehensive approach to comparative effectiveness review (CER) and evidence synthesis.

42. Preventing Sudden Cardiac Death: Harnessing the Power of Decision Analysis, Bayesian Statistics, and Clinical Trials (1R01-HS018505-01)

Principal Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 09/30/2009-03/31/2014

Total Costs: \$1,475,687

We have four specific aims: (1) To develop a generalizable decision modeling framework for the prevention of SCD; (2) To use Bayesian statistical techniques to devise a model for predicting patient and population health and economic outcomes; (3) To use the framework from Specific Aim 1, the Bayesian model from Specific Aim 2, and patient level data from existing clinical trials, to explore timely clinical and policy questions; and (4) To develop a web-based dissemination system to allow providers and policy makers to interact with the decision modeling framework and to explore clinical and policy questions as evidence evolves.

43. Evaluation of Computerized Decision Support for Managing Lung Nodules (7R01CA117840-06)
Principal Investigator: Michael Gould MD, MS
Co-Principal Investigator: Gillian D. Sanders Ph.D
National Cancer Institute
Project Period: 06/27/2005 – 2/28/2014
Current Year Costs: \$179,110
This research aims to evaluate a novel, computer-based system for improving management in patients with solitary pulmonary nodules, which sometimes represent a curable form of lung cancer. By evaluating and eventually implementing the system, we aim to reduce the frequency of unnecessary surgery in patients with non-cancerous lung nodules, and reduce the number of delayed surgeries that may lead to missed opportunities for cure in patients with cancerous nodules
44. ICD Therapy in Patients with Congestive Heart Failure (1R01-HL093071-01A1)
Principal Investigator: Sana M. Al-Khatib MD, MS
Co-Investigator: Gillian D. Sanders Ph.D.
National Heart Lung Blood Institute
Project Period: 07/15/2009-12/31/2013
Current Year Costs: \$440,368
To examine the current use of primary prevention implantable cardioverter defibrillator (ICD) in clinical practice.
45. Systematic Reviews of Cancer Screening Literature for Updating American Cancer Society Breast Cancer Screening Guidelines
Principal Investigator: Evan Myers MD, MPH
Co-Investigator: Gillian D. Sanders Ph.D.
American Cancer Society
Project Period: 5/20/2013-3/20/2014
Total Costs: \$371,399
The overall goal of the proposed work is to support the American Cancer Society (ACS) Guidelines Development Panel (GDP) in the development of evidence-based recommendations that meet the criteria outlined by the Institute of Medicine (IOM) 2011 report “Clinical Practice Guidelines We Can Trust.”
46. Future Research Prioritization (Amendment)
Principal Investigator: Gillian D. Sanders Ph.D.
Patient Centered Outcomes Research Institute
Project Period: 7/1/2013-12/31/2014
Current Year Costs: \$338,822
Amendment to original contract to perform future research prioritization for targeted funding topics.
47. Development of Topic Briefs being Considered for Targeted Funding Announcements (Original Contract and Amendments)
Principal Investigator: Gillian D. Sanders Ph.D.
Patient Centered Outcomes Research Institute
Project Period: 2/15/2013-1/15/2015
Current Year Costs: \$277,111
Original contract and subsequent amendments to develop two additional short topic briefs in order to evaluate PCOR related topic nominations and synthesize this information to be used by advisory panelists to perform prioritization of these topics for PCORI targeted funding announcements.
48. Treatment of Symptoms in Multiple Sclerosis
Principal Investigator: Gillian D. Sanders Ph.D.
Patient-Centered Outcomes Research Institute
Project Period: 1/12/2015-3/14/2015
Total Costs: \$29,819
The Duke University Evidence-based Practice Center shall create a narrative review report that expands on the April 2013 topic brief it created for PCORI titled “Comparative effectiveness of treatment programs for

recurring/remitting multiple sclerosis (MS)” to incorporate comparative effectiveness of disease-modifying therapies (DMTs) on multiple MS symptoms and other treatments of symptoms of MS.

49. Decision Aid Portfolio Analysis (PCO-DAWG2014)

Principal Investigator: Gillian D. Sanders Ph.D.

Patient-Centered Outcomes Research Institute

Project Period: 12/1/2014-2/28/2015

Total Costs: \$66,553

The goals are to develop an approach for identifying decision aids and clinical prognostication tools within PCORIs portfolio of projects; to develop and execute an approach for categorizing decision aid projects based on decision aid literature; and to make recommendations for analyzing the portfolio by decision aid quality based on the current landscape of standards and recommendations related to decision aid development and implementation

50. Catheter Ablation for Atrial Fibrillation: Topic Refinement and Systematic Review

Principal Investigator: Andrea Skelly Ph.D.

Co-Investigator Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 7/16/2013-2/11/2015

Total Costs: \$74,509 (Duke subcontract)

To perform a topic refinement followed by a small systematic review on the use of catheter ablation for treatment of atrial fibrillation.

51. Comparative Effectiveness Review: Attention Deficit/Hyperactivity Disorder

Principal Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 3/2/2015-5/30/2016

Total Costs: \$625,000

To perform as part of the EPC program a topic refinement and subsequent systematic review on the diagnosis and treatment of children and adolescents with ADHD

52. Comparative Effectiveness Review: Management of Infertility

Principal Investigator: Evan Myers MD, MPH

EPC Director/Co-Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 3/2/2015-5/30/2016

Total Costs: \$625,000

To perform as part of the EPC program a topic refinement and subsequent systematic review on management of infertility

53. Comparative Effectiveness Review: Labor Dystocia

Principal Investigator: Evan Myers MD, MPH

EPC Director/Co-Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 4/20/2015-8/15/2016

Total Costs: \$480,000

To perform as part of the EPC program a topic refinement and subsequent systematic review on treatment of women with labor dystocia

54. Treatment Strategies for Patients with Lower Extremity Peripheral Venous Disease

Principal Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality/Centers for Medicare and Medicaid Services

Project Period: 9/14/2015-9/5/2016

Total Costs: \$500,000

To perform as part of the EPC program a systematic review the diagnosis and treatment of peripheral venous disease.

55. Panel on Cost Effectiveness in Health and Medicine

Principal Investigator: Gillian D. Sanders Ph.D.

Tufts University (Sponsor: Robert Wood Johnson Foundation)

Project Period: 12/15/2013-12/31/2016

Total Costs: \$33,397 (Duke Subcontract)

The medical editor will participate in all Panel meetings and calls and help with the structure of the book. She will work with individual chapter leads to create structured templates for their sections and to develop a consistent and reader-friendly way of highlighting material and recommendations that are new or modified. She will provide substantive editing to assist the 2nd Panel in knitting together the chapters into a well-written, coherent update, as well as copy editing to ensure that the final work meets the publisher's technical specifications.

56. Panel on Cost Effectiveness in Health and Medicine

Principal Investigator: Gillian D. Sanders Ph.D.

Tufts University (Sponsor: Gates Foundation)

Project Period: 07/01/2014-12/31/2015

Total Costs: \$10,778 (Duke Subcontract)

The medical editor will participate in all Panel meetings and calls and help with the structure of the book. She will work with individual chapter leads to create structured templates for their sections and to develop a consistent and reader-friendly way of highlighting material and recommendations that are new or modified. She will provide substantive editing to assist the 2nd Panel in knitting together the chapters into a well-written, coherent update, as well as copy editing to ensure that the final work meets the publisher's technical specifications.

57. Value of Information Analysis: PCORnet Aspirin Maintenance Dosage Trial

Principal Investigator: Gillian D. Sanders Ph.D.

Patient-Centered Outcomes Research Institute

Project Period: 1/5/2015-4/30/2016

Total Costs: \$136,150

To use the example of the proposed PCORnet Aspiring Maintenance Dosage Trial (Aspirin Trial) to compare maximal and minimal value of information (VOI) models and to consider how VOI models can be used to inform trial design decisions. The results of this work will not be used directly to inform decisions about whether or not to conduct the Aspirin Trial, or to mandate design choices, but rather to compare, test, and provide evidence of the most appropriate and efficient VOI methods.

58. Patient and Provider Prioritization of PCSK9 Inhibitor Outcomes

DukeIDIQ03.01.14 (PCSK9 Inhibitors)

Principal Investigator: Gillian D. Sanders Ph.D.

Patient-Centered Outcomes Research Institute

Project Period: 08/29/16-11/14/16

Total Costs: \$56,211

To seek patient and provider input to inform development of a protocol for a clinical trial comparing PCSK9 inhibitors with conventional therapy in patients with hypercholesterolemia.

59. Topic Brief: Pancreatic Cancer

DukeIDIQ03.01.14 (Pancreatic Cancer)

Principal Investigator: Gillian D. Sanders Ph.D.

Patient-Centered Outcomes Research Institute

Project Period: 8/29/2016-11/16/2016

Total Costs: \$11,909.00

Topic brief to evaluate the comparative effectiveness of treatments for pancreatic ductal adenocarcinoma (PDAC) and its subtypes.

60. Office of Womens Health: Topic Development

Principal Investigator: Gillian D. Sanders Ph.D.

Agency for Healthcare Research and Quality

Project Period: 10/24/2016-1/16/2017

Total Costs: \$125,000

To conduct topic development briefs for 5 women's health topics: obesity, caregivers, maternal health, mental health, nutrition.